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Experimental models that faithfully reflect both normal physiological and pathological 
conditions represent an essential cornerstone of both the basic and applied sciences. However, 
the degrees to which these models represent actual in vivo conditions and environments greatly 
affect their ability to accurately produce clinically relevant responses to stimuli such as drug 
exposures. This dissertation introduces an in vitro kidney proximal tubule model that aims to retain 
tissue architecture, cell organization, cell-matrix and cell-cell interactions, and physiological 
cellular responses in long-term culture, and assess its ability to preserve differentially and 
functionally stable primary cells during exposure to drugs known to be nephrotoxic. These features 
are achieved by encapsulating suspended harvested viable proximal tubule fragments containing 
their epithelial cells in a three-dimensional hyaluronic acid (HA) hydrogel matrix. Proximal tubule 
fragment (i.e., “organoid”) encapsulation, and not their isolated cells suspensions, in the hydrogel 
endows the model with the capability to retain native cellular organization, extracellular matrix, and 
intra- and extra-cellular interactions, while limiting non-native cell-polymer interfaces. Data 
collected for these cultures indicate that proximal tubule epithelial cells sustain cellular 
gluconeogenic potential, differential markers, and functional ligands. Moreover, these kidney cells 
in vitro were capable of responding to exogenous agents (i.e., drug introductions) with induction of 
in vivo-relevant gene and protein biomarkers as well as accurate cytokine, cytochrome, and 
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metabolite expression patterns.  
The utility of the model for assessing potential nephrotoxic agents was further validated by 
comparison to the “gold standard” of current in vitro toxicology: immortalized cell monolayers 
grown on plastic. Results demonstrate significant improvements in cell phenotypic fidelity for 3D 
organoid cultures over cells supported via standard in vitro culture techniques that produce most 
clinically measured biomarkers. The obtained results indicate that preservation of the cellular 
microenvironment is key to not only sustaining functional proximal tubule cells in vitro but also in 
preserving their natural responses to the same nephrotoxic indicators as expressed in animal 
toxicity models. The proposed 3D in vitro culture model bridges the gap between overly simplistic 
cellular and costly in vivo assessment, and opens possibilities for direct, reliable and predictive 
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CHAPTER 1 
INTRODUCTION TO THE DISSERTATION 
In vitro-sustained cellular cultures are the most promising and accessible toxicity and 
biomarker assessment tools used routinely during preclinical drug development. Unlike their in 
vivo or animal counterparts, in vitro systems can be easily propagated and scaled up in both 
academic and industrial settings, are relatively inexpensive, and currently are the only assessment 
models capable of high-throughput evaluation. Unfortunately, traditional cell culture approaches 
that utilize immortalized or genetically transformed cell lines on two dimentional (2-D) plastic cell 
culture surfaces are over-simplified and incapable of reproducing the complexity of whole tissue 
processes, namely cellular toxicity (as explained in Chapter 2). The goal of this research was to 
develop improved, more in vivo-relevant cell culture methods that would retain the benefits of 
current in vitro techniques while improving reliability and predictive capabilities for in vivo 
translation of the acquired data, particularly for preclinical studies on drug toxicity screening.      
While current dogma recognizes that different variables present in the cellular 
microenvironment contribute to cellular changes, initiation of damage-specific pathways in cellular 
models relies both on differentiation and functional maintenance of cells as well as sustained 
signaling cross-talk within the cellular niche (also reviewed in Chapter 2). Reliable production of in 
vivo-like biomarkers of cell toxicity within cell cultures has proven difficult. Maintenance of 
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organotypic cellular interactions appears to be required for cell fidelity necessary to recapitulate 
cell toxicity responses representative of those in vivo. This reinforces the necessity to maintain 
cellular microenvironments during in vitro culture models of toxicity. Traditional 2-D monolayer cell 
cultures on plastic cannot provide these requirements.  
These observations form the overarching hypothesis driving this dissertation: that cell-cell 
and cell-matrix interactions resembling structure and function of native tissue architectures are 
critical for guiding and maintaining cellular identities in vitro and producing clinically-relevant 
toxicity biomarkers in culture (reviewed in Chapter 2). To explore this hypothesis, an organoid 
kidney culture model that retains native cell-ECM interactions, intercellular communication, and 
3-D organization has been developed, fully characterized (see Chapter 3) and validated (see 
Chapters 4 and 5). An in vitro organoid kidney proximal tubule culture model (Chapter 3) provides 
minimal perturbations to critical cell-cell and cell-matrix interactions in kidney proximal tubules, 
prolonging kidney cell functions and viability while concurrently eliminating unpredictable 
non-native cell-polymer interactions that often plague other 3-D tissue culture models. Extensive 
characterization of the kidney proximal tubule organoid culture model (Chapter 3) based on: 1) 
cellular histological and molecular markers, 2) cellular metabolic activity, 3) cellular polarization, 
and 4) gluconeogenic potential are all reported. Subsequent validation of the 3-D organoid tissue 
culture model (detailed in Chapters 4 and 5) against the ‘gold standard’ for in vitro toxicological 
evaluation -- kidney cell monolayers grown on 2-D surfaces -- compares production of known, 
validated clinical biomarkers of kidney toxicity in both traditional 2-D and 3-D organoid cell culture 
models in exposures to four clinical drugs known for nephrotoxicity. The study seeks to prove the 
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concept that preservation of in vivo-like organization within kidney organoid constructs will elicit 
more relevant and reliable pharmacological toxicity and toxicity marker up-regulation compared to 
2-D cell cultures. Specifically, Chapter 3 describes how this 3-D culture methodology elicits toxicity 
markers for four clinically used drugs in 96-well plate assays over several weeks – a significant 
difference from drug responses from common immortalized cell lines HEK293 and LLC-PK1.  
The chapter analyzes the results and proposes broad reaching implications for in vitro toxicity 
assessments. This functional analysis is extended in Chapter 4 to further evaluate and 
quantitatively assess the ability of each in vitro culture system to predict kidney drug toxicity in vivo 
using clinically accepted biomarkers of in vivo kidney toxicity. Ultimately, the new in vitro 3-D 
organoid kidney tissue model confirms the hypothesis that endowing culture systems long-term 
with native cellular interactions instead of employing a minimalist’s approach to in vitro cell culture 
better ensures that not only are biological requirements for creating and sustaining tissue 
replacement models met, but that the data obtained are relevant and impacting.  
All of the advantages attributed to the proposed high-throughput 3-D organoid kidney culture 
systems support the value of the cell culture model that yields better-quality, more accurate, 
tissue-specific information to significantly improve the assay for nephrotoxicity, its predictive value, 
and more accurate translation between in vitro, animal, and clinical human studies. Moreover, 
such capabilities would open new avenues for application of analogous in vitro cell-based 
organoid models for other organ toxicities (e.g., liver) in addition to new research that integrates 
data utilization, improves drug screening results, and yields higher quality pharmacokinetic 
assessments. Further developments using 3-D models that focus on production and preservation 
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of fully native (and not minimalist equivalent) extracellular matrix, cell-cell interactions, relevant 
tissue architectures, and maintenance of both chemical and mechanical tissue-like stimulation 
using bioreactors are suggested to be critical for advancing in vitro cell-based experimental 
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3-D and 2-D culture
Drug candidate and toxicity screening processes currently rely on results from early-stage in vitro cell-based
assays expected to faithfully represent essential aspects of in vivo pharmacology and toxicology. Several in
vitro designs are optimized for high throughput to beneﬁt screening efﬁciencies, allowing the entire libraries
of potential pharmacologically relevant or possible toxin molecules to be screened for different types of cell
signals relevant to tissue damage or to therapeutic goals. Creative approaches to multiplexed cell-based assay
designs that select speciﬁc cell types, signaling pathways and reporters are routine. However, substantial per-
centages of new chemical and biological entities (NCEs/NBEs) that fail late-stage human drug testing, or re-
ceive regulatory “black box” warnings, or that are removed from the market for safety reasons after
regulatory approvals all provide strong evidence that in vitro cell-based assays and subsequent preclinical
in vivo studies do not yet provide sufﬁcient pharmacological and toxicity data or reliable predictive capacity
for understanding drug candidate performance in vivo. Without a reliable translational assay tool kit for
pharmacology and toxicology, the drug development process is costly and inefﬁcient in taking initial in
vitro cell-based screens to in vivo testing and subsequent clinical approvals. Commonly employed methods
of in vitro testing, including dissociated, organotypic, organ/explant, and 3-D cultures, are reviewed here
with speciﬁc focus on retaining cell and molecular interactions and physiological parameters that determine
cell phenotypes and their corresponding responses to bioactive agents. Distinct advantages and performance
challenges for these models pertinent to cell-based assay and their predictive capabilities required for accu-
rate correlations to in vivo mechanisms of drug toxicity are compared.
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Cell-cell and cell-matrix interactions control cell phenotypes and functions in vivo.  
Maintaining these interactions in vitro is essential to both produce and retain cultured cell fidelity to 
normal phenotype and function in the context of drug efficacy and toxicity screening.  
Two-dimensional (2-D) cultures on culture plastics rarely recapitulate any of these desired 
conditions. Three-dimensional (3-D) culture systems provide a critical junction between traditional, 
yet often irrelevant, in vitro cell cultures and more accurate, yet costly, in vivo models.  This study 
describes development of an organoid-derived 3-D culture of kidney proximal tubules (PTs) that 
maintains native cellular interactions in tissue context, regulating phenotypic stability of primary 
cells in vitro for up to 6 weeks. Furthermore, unlike immortalized cells on plastic, these 3-D 
organoid kidney cultures provide a more physiologically relevant response to nephrotoxic agent 
exposure, with production of toxicity biomarkers found in vivo. This biomimetic primary kidney 
model has broad applicability to high-throughput drug and biomarker nephrotoxicity screening, as 
well as more mechanistic drug toxicology, pharmacology, and metabolism studies.  
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In vivo cell-cell interactions, and more broadly, the contextual communication characteristics 
of the tissue microenvironment (i.e., matrix-mediated, haptotactic, chemotactic, biomechanic, 
paracrine, autocrine signals), dictate cell phenotype and are required to produce and maintain 
tissue-like responses in vitro (1-8). Many physiological variables including cell-cell interactions, 
cell-matrix communication, matrix chemical composition, matrix mechanics, matrix porosity, 
chemotactic gradients of soluble cell signals, cell oxygenation, and 3-D matrix architectures are 
critical for producing in vivo-like cell behavior (1, 4-6, 9). Cell proliferation, polarization, migration, 
signaling, and gene expression in vitro depend on both presence and proper presentation of these 
signals. However, no single variable alone achieves tissue-like organization to elicit tissue-like 
functions; many (if not all) of these chemical, mechanical and structural parameters must be 
satisfied in any in vitro culture to recapitulate in vivo cell responses. Available in vitro bioreactors 
using highly sophisticated control systems and dynamic inputs to control cell growth in 3-D 
scaffold systems (10) is not informed at the appropriate cell level with requisite design criteria to 
recapitulate in vivo complexity in several tissue types, particularly at levels of organ heterogeneity.  
Hence, a compelling need remains for improved cellular models that capture the complexity of 
tissue organization in vitro in a reproducible manner to reproduce key traits (e.g., responses to 
drugs, regenerative tissue function) and study processes only accessible currently in mammalian 
animal models. 
Development of a physiologically accurate and functionally high-fidelity kidney tissue 
surrogate is of particular interest for kidney transplant clinical demands (11-14).  Another impact 
32 
 
lies in pharmaceutical drug development needs, as many drugs and new drug candidates 
inadvertently cause kidney toxicity (15). Currently, commercially marketed drugs account for 25% 
of acute kidney injury in critical care patients (16). Next to liver toxicity, kidney toxicity is the second 
leading indicator for drug candidate attrition (16). Furthermore, since current clinical methods such 
as blood urea nitrogen (BUN) and creatinine measurements suffer from an intrinsic inability to 
recognize early signs of kidney damage (17, 18), a great need exists for cell-based systems 
capable of reliable and sensitive assessment of kidney toxicity. Such systems would benefit from 
numerous advances in high-throughput (HTS) assessment as well as recent developments in 
biomarker validation using toxicogenomics, proteomics, and metabolomics (15). The few 
extensive biomarker studies conducted -- the Innovative Medicines for Europe (InnoMed) PredTox 
project, ILSI Health and Environmental Sciences Institute initiative, Predictive Safety Testing 
Consortium -- were limited by their reliance on costly in vivo models due to limitations inherent in in 
vitro cell culture screens. Additionally, these efforts required consortia of pharmaceutical industry, 
academia, and regulatory agencies due to the excessive expenses and workload associated with 
the studies (15). Hence, development of improved in vitro culture approaches better reflective of in 
vivo cell behaviors and reactions to drugs would significantly impact both the cost and accessibility 
of future HTS work.  
Reliable kidney toxicity assessment requires retention of cellular structural and biochemical 
pathways; nephrotoxicity is a complex process involving drug metabolism using cytochrome (CYP) 
P450, biotransformation using intra- and extracellular enzymes, dynamic changes in cellular 
accumulation as a function of uptake and drug removal via specific transporters and inflammatory 
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process regulation (19-21). Currently, the gold standard for kidney-like culture models involves use 
of primary or immortalized cell lines grown on conventional 2-D tissue culture plastic surfaces. 
Although convenient and relatively simple to employ, the ‘petri dish’ approach leads to quick 
de-differentiation of primary cells in vitro, most probably through loss of tissue-like interactions on 
2-D plastic (22, 23). Furthermore, transformed kidney cell lines have limited cellular machinery, 
including transporters, ligands associated with endocytosis, enzymes involved in 
biotransformation of molecules, and CYP P450 metabolism, making them intrinsically incapable of 
reacting to complex external pathophysiological stimuli with in vivo-relevant biomarkers (5, 7, 
23-27). Due to the limiting functional cell equivalence on 2-D surfaces, cell assay data obtained in 
response to toxic drug and environmental agents are typically limited to simple observations of 
changes in cell viability and proliferation, both of which have little predictive value in vivo. 
Furthermore and perhaps most importantly, no tangible improvements of 2-D cell culture are 
feasible as studies will always be constrained by the fundamental limitations of rudimentary cell 
monolayer and (frequently) monoculture interactions on tissue culture plastic. More complex in 
vitro cell cultures that preserve tissue-like 3-D cell-cell interactions, tissue architecture and 
communicative biochemistry are needed to better assess complex cellular mechanisms in a 
clinically significant fashion. 
The current nephrotoxicity assay design focused on toxicity processes associated with the PT, 
an essential central component of the functional nephron. The PT is a hollow tube comprising a 
basement membrane lined by epithelial cells, and is the primary site of clinical kidney toxicity 
instigated by external stimuli, such as heavy metals, dyes and drugs (28). Susceptibility of PTs to 
34 
 
environmental assaults is most likely due to the significant epithelial surface area provided in this 
part of the nephron, as well as the large number of active transporters possibly hijacked by small 
molecules entering the nephron. Encapsulation of harvested viable intact PTs, and not simply the 
epithelial cells that line their lumens, directly into a well-characterized biologically derived matrix 
avoids unpredictable, confounding cell-polymer matrix interactions, while preserving native 3-D 
cell matrix environments and cell-cell physiological interfaces. Together this cellular context 
ensures cell maintenance, signaling and more accurate, extended in vivo-like epithelial cell 
responses.   
Hyaluronic acid (HA)-based hydrogels used to encapsulate PTs are already well-established 
in preserving tissue-like architectures and cell interactions in several tissue regeneration and 3-D 
bioreactor culture models (29-32). Furthermore, HA is a natural polymer present in almost all 
bodily tissues, including the kidney. Primary proximal tubule epithelial cell viability, differentiation 
potential and functionality were all used to assess and validate this newly developed 3-D organoid 
culture for up to 2 months. This culture response to known nephrotoxic agents compared 
cytochrome P450 enzyme induction, metabolite production, and kidney injury-1 (Kim-1) protein 
up-regulation – accepted markers for typical drug toxicity screens.  
Methods 
Construct preparation  
Male C57BL/6 mice (6-8 weeks) were purchased from Jackson Laboratory (Bar Harbor, 
USA). All animals were euthanized using carbon dioxide according to approved University of Utah 
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IACUC protocols and PTs were isolated immediately following literature-established procedures 
using standard aseptic conditions in a BSL2-certified laminar flow hood (33). Briefly, murine 
kidneys were removed surgically and cleaned of the kidney capsule, blood vessels and ureter. 
Between all steps tissue was stored in ice-cold KREBS solution (145 mM NaCl, 10 mM HEPES, 5 
mM KCl, 1 mM NaH2PO4, 2.5 mM CaCl2, 1.8 mM MgSO4, 5 mM glucose, pH 7.3) (34). The tissue 
was then mechanically disrupted using sharp razor blades and enzymatically digested for 30 min 
in enzyme solution (10ml KREBS, 2mg/ml hyaluronidase (Worthington Biochemical Corporation, 
USA), 3mg/ml collagenase IV (Worthington Biochemical Corporation, USA), 0.1mg/ml DNase I 
(Sigma-Aldrich Chemical, USA)) at 37
ᵒ
C (34). PTs were enriched by sequential 250µM and 80 µM 
sieving of the resulting digested nephron sections. PTs were then pelleted from the resulting 
suspension in KREBS by centrifugation for 15 min at 12,000 rpm. Proximal tubule yield was 
estimated using a hemocytometer. 
The 3-D organoid proximal tubule cultures were fabricated by combining purified PTs with 
1.5% commercial thiol-modified carboxymethylated hyaluronic acid (HA) (carboxymethyl, thiol 
modified: CMHA-S) and 7.5% commercial poly(ethylene glycol) diacrylate (PEGDA) bifunctional 
polymer electrophile (30, 32, 35). Both gel-forming GMP biomedical grade polymers were 
generously provided by Sentrx Animal Care (Salt Lake City, USA). CMHA-S and PEGDA were 
resuspended in PBS
++
, sterile filtered using 0.22 µm cell culture syringe filters (ISC Bioexpress, 
USA), and mixed in 4:1 ratio with PTs. Constructs were made by casting 50 µL of PT/gel mixture 
into Teflon-AF® -coated 96 well plates (see below). Then the 3-D organoid gel precursor matrix 
was crosslinked for 35 min in a cell incubator at 37
ᵒ
C (5% CO2 and 95% air). Proximal tubule 
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media consisting of 1% fetal calf serum (Invitrogen, USA), 5% sodium pyruvate (Invitrogen, USA), 
10% non-essential amino acids (Invitrogen, USA), 10% insulin/transferrin/selenium (Invitrogen, 
USA), 1% antibiobic-antimycotic (Invitrogen, USA), 0.9 µg of hydrocortisone (Invitrogen, USA), 
and Dulbecco's modified Eagle medium (DMEM)-Ham's F-12 with 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) and L-glutamine (Invitrogen, USA) 
(33) was then added to final HA hydrogel constructs containing viable tubules (100 µL/well) and 
exchanged every 2 days for maximum cell viability.  
The Teflon AF®-coated 96-well culture plates (150 µL/well) were prepared according to 
previously published protocols (36) using non-tissue culture polystyrene plates (ISC Bioexpress, 
USA) and Teflon-AF® (Dupont, USA) dissolved in FC-40 (3M, USA) organic solvent. Solvent was 
removed using vacuum drying in elevated temperature (56ºC), and coated plates were sterilized 
using UV for 30 min before use (36).   
Analysis of cell viability  
Proximal tubule epithelial cell viability in the 3-D organoid constructs was assessed using 
CyQuant NF® (Invitrogen, USA) and MTS (Fisher, USA) viability assays. All solutions for both 
assays were prepared according to each manufacturer’s instructions. All constructs were treated 
for 1 hour with 0.01 mM peroxide in proximal tubule media in the incubator to oxidize all remaining 
non-crosslinked thiols in the CMHA-S-based HA gel. MTS and CyQuant NF® reagents were then 
applied directly on top of the 3-D organoid cultures and incubated for 1 hour at 37
ᵒ
C. When using 
CyQuant NF®, the supernatant over the gel was fluorometrically analyzed, and with MTS, the 
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optical density of the entire construct was analyzed, both using a Synergy 2 microplate reader 
(CyQuant NF® fluorescence at 485 nm excitation and 530 nm emission; MTS absorbance at 490 
nm). HA hydrogel without cells was used as background control.  
Analysis of cell differentiation status  
Proximal epithelial cell differentiation status was assessed using reverse-transcriptase 
polymerase chain reaction (RT-PCR) and immunofluorescence. RT-PCR for common nephron 
markers was performed at 0-8 weeks of 3-D organoid culture: AQP1 (proximal tubule gene 
marker), AQP2 (distal tubule gene marker), NCC (collective tubule gene marker), GAPDH 
(housekeeping gene), megalin (functional ligand). RNA was extracted by solubilizing the entire 
construct in TRIzol® (Invitrogen, USA), flash freezing it in liquid nitrogen, homogenizing the 
construct using mortar and pestel, and extracting RNA using the standard TRIzol® protocol. RNA 
was reverse-transcribed into cDNA using a Superscript III kit (Invitrogen, USA) and message for 
the genes of interest was isolated using PCR with gene-specific primers (see Supplementary 
Tables). RT-PCR was performed on an iCycler (Bio-Rad, USA) using GoTaq Green mastermix 
(Promega, USA) following the manufacturer’s suggestions. All PCR samples were run with 40 
denaturation cycles under the following conditions: 30 sec at 95
ᵒ









C (NCC), 1 min elongation at 72
ᵒ
C. PCR 
products were visualized on a 1.5% agarose gel (Fisher, USA) containing ethidium bromide using a 
Bio-Rad gel imager. 
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Immunofluorescence was performed on the entire 3-D organoid construct. Scaffolds were 
fixed using 4% paraformaldehyde overnight at 4
ᵒ
C, blocked using anti-goat serum for 2 hours at 
room temperature (RT), stained with primary antibody or lectin for 3 days in the 4
ᵒ
C, and incubated 
with secondary Alexa-488 goat-antimouse IgG antibody and PI for 1 hour at RT. Primary AQP1 
antibody (Chemicon, USA) and PHA-E-FITC (Vector Labs, USA) were used at 1:2000, and OAT-1 
antibody (Abbiotec, USA), connexin 43 (Millipore, USA), and α3 antibody (Santa Cruz 
Biotechnology) at 1:1000 dilution. Constructs were imaged using an AR1 Nikon inverted 
microscope (University of Utah Imaging Core facilities).  
Analysis of cell functionality  
Cell functions in the 3-D organoid hydrogel cultures were analyzed by measuring cell-specific 
enzymatic functions and their ability to endocytose drugs. Cathepsin B, alkaline phosphatase, and 
γ-glutamyl-transferase were assessed at 0-8 weeks of culture. Cathepsin B in the 3-D organoid 
constructs was measured using a fluorescence-based kit (BioVision, USA). All solutions were 
prepared according to manufacturer’s protocol. Cells in PTs were lysed by adding 50 µL of chilled 
lysis solution/well and vigorous mixing with the gel for 10 min in the hood at RT. The reaction was 
initiated by adding 50 µL of the reaction solution provided and 2 µL of substrate provided in the kit. 
Identical hydrogel with no cells was used as a control. All samples were read fluorescently using 
400 nm excitation and 505 nm emission filters (slit width 2nm) on a spectrophotometer (Synergy 2). 
Alkaline phosphatase activity was measured in 3-D cell constructs using SensoLyte® kit 
(AnaSpec, USA). All solutions were prepared according to the manufacturer’s instructions. 
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Reaction mixture from the kit (50 µL) was added directly to the construct and incubated for 30 min 
at 37°C. Chromogenic product was estimated using a spectrophotomer at A405 and referenced 
against the provided optical standard. Identical hydrogel without cells was used as background. 
γ-glutamyl-transferase activity was assessed according to standard chromogenic assay 
protocols (37). Each construct was preincubated with 50 µL of assay solution (150 mM NaCl and 10 
mM Tris-HCl, pH 8.5) for 5 min at RT. The assay reaction was begun by adding 50 µL 5mM 
γ-glutamyl-p-nitroaniline (Sigma Aldrich, USA) with 100mM glycylglycine (Sigma Aldrich, USA) 
chromogenic substrate. The reaction proceeded for 20 min in the incubator and then stopped using 
10% acetic acid. Amounts of chromogenic product produced were determined using a 
spectrophotomer at A405 and referenced against that for 1mM p-nitroanilide (Sigma Aldrich, USA). 
PT epithelial cell ability to endocytose was determined by estimating cell viability upon 
exposure to drug neomycin (Sigma Aldrich, USA) in the presence of endocytosis inhibitor 
colchicine (Sigma Aldrich, USA). Neomycin was directly resuspended in the proximal tubule media. 
Colchicine was diluted from 20 mM stock solution in 100% dimethyl sulfoxide (DMSO) using 
proximal tubule media. Both drugs were sterile filtered prior to exposure to constructs. Cell viability 
was assessed using CyQuant NF® as specified above.  
Analysis of cell senescence and gluconeogenesis  
Proximal tubule epithelial cell senescence was quantified using β-galactosidase activity 
according to a published protocol (38). Briefly, cells within the hydrogel were lysed using 250 µL of 
lysis buffer (5 mM 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate, 40 mM citric acid, 
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40 mM sodium phosphate, 0.5 mM benzamidine, and 0.25 mM phenylmethanesulfonyl fluoride, pH 
6.0), decellularized by vortexing and collecting the supernatant. The reaction was initiated with 150 
µL of reaction buffer with 1.7 mM of 4-methylumbelliferyl- β-galactopyranoside) to 100 µL of cell 
lysate and 50 µL of lysis buffer, and then stopped by adding 500 µL of sodium carbonate after 2 
hours. Fluorescence (ex: 360 nm, em: 465 nm) was read against HA blank control gel without cells 
as background. 
Glucose concentration was determined using a HK kit (Sigma Aldrich, USA), which quantifies 
the amount of glucose present as a function of its phosphorylation by adenosine triphosphate 
(ATP) to glucose-6-phosphate (G6P) and concurrent reduction of oxidized nicotinamide adenine 
dinucleotide (NAD) to NADH. All reagents were reconstituted and calculations were performed 
according to manufacturer’s instructions. An internal glucose standard of known concentration was 
used as a positive calibration control. 
Analysis of nephrotoxicity  
Proximal tubule epithelial cell expression of CYP2E1 and Kim-1 was determined using 
immunofluorescence. Hydrogel scaffolds containing organoids were exposed to 1% acetone 
(Fisher, USA) or 1.7 mM cisplatin for 3 days. Cisplatin (Sigma Aldrich, USA) was stored as 200 mM 
stock solution in DMSO, diluted to its final concentration, and sterile filtered using 0.22µm filter prior 
to application to cell constructs. After culture exposure to drug, 3-D organoid cultures were fixed 
using 4% paraformaldehyde overnight at 4
ᵒ
C, blocked using signal enhancer (Invitrogen, USA) for 
1 hour at RT, stained with primary antibody for 3 days at 4
ᵒ
C, and incubated with secondary 1:1000 
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Alexa-488 goat-antimouse IgG antibody (Invitrogen, USA) for 2 hours at RT. CYP2E1 antibody 
(Millipore, USA) was used at 1:1000 and R9 Kim-1 antibody used at 1:500 dilution. Cell constructs 
were imaged using an Olympus FV1000 spectral confocal microscope (University of Utah Imaging 
Core facilities).  
Analysis of cisplatin metabolites 
Metabolite production was assessed using HPLC after both 1 hour and 6 hours of 3-D culture 
incubation with 1.7 mM cisplatin. Cisplatin was resuspended in DMEM-Ham's F-12 protein-free 
media from a 200 mM DMSO stock solution. Media with platinum species were analyzed directly. 
Hydrogel constructs were weighed, suspended in 4 times w/v 0.25 M sucrose solution, 
homogenized, and centrifuged at 9000g following by 19000g for 15 min each time. Samples (10µL) 
of supernatants from constructs and media were then loaded onto an Atlantis dC18 3 µm column 
(2.1x30mm). The column was pre-equilibrated in 50 mM potassium phosphate buffer, pH 6.0 
(mobile phase A). Samples were eluted at 0.2 ml/min rate by a linear gradient starting from 100% 
mobile phase A and reaching 100% solvent B (0.45% acetonitrile in mobile phase A) after 10 min, 
followed by 5 min wash in mobile phase A at 1ml/min for 5 min. Platinum species were detected at 
280nm using a Finnigan Surveyor HPLC system (Waters, USA). Protein-cisplatin controls were 
prepared by mixing 2 mM cisplatin with 2 mM NAC (Sigma Aldrich, USA), Cys-Gly (Sigma Aldrich, 





Analysis of proximal tubule cell cytokine expression  
MCP-1, TNFα, RANTES, MIP-1α, IL-6 and IL-1ß cytokine release was assessed in the 
proximal tubule media samples after 3 days of drug incubation at the corresponding EC50 
concentrations for each drug (doxorubicin (DOX) at 1.4 µM, colchicine (Col) at 24.4 µM, PAP at 
24.9 µM, cisplatin (Cisp) at 0.42 mM). Cytokines were captured using a commercial cytometric 
bead array kit (BD
TM
 Biosciences, USA) according to manufacturer’s instructions and their 
concentrations were measured by averaging fluorescence of at least 300 beads per analyte. All 
protein concentrations were calculated by comparing measured sample values to the analyte 
fluorescence standard curve run (see Supplementary Figures) with every assay using 
commercially provided cytokine controls. Only values that fell into standard curves’ dynamic range 
were considered for sample evaluation. Data acquisition was performed using 5-color FACScan 
Analyzer (BD
TM
 Biosciences, USA) with a benchtop analyzer using two lasers for fluorochrome 
excitation (15 mW argon (488 nm) and 25 mW red diode (637 nm)). Free Weasel (Walter & Eliza 
Hall Institute) software was used to import and quantify collected for CBA data.  
Statistical analysis  
GraphPad Prism 5 (GraphPad Software, Inc.) and Excel 2010 (Microsoft, Inc.) statistical 
software packages were used for data analysis. Independent samples used cells isolated from 
separate mice. Experiments that produced data and their corresponding normalization values were 
expressed as mean±S.E (standard error). Experiments that used normalization values from 
separate measurements appear as mean±95% confidence intervals. CBA data were analyzed 
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using unpaired student t-test and adjusted for multiple comparisons using Hochberg’s procedure. A 
post-hoc student’s t-test was used to determine statistically significant differences between 
samples (p<0.05). 
Results 
Proximal tubule isolation purity and efficiency  
The protocol to isolate proximal tubule-enriched subpopulations from freshly harvested intact 
C57BL/6 murine kidneys was reliable and efficient. PTs were extracted from whole kidneys via 
enzymatic digestion and mechanical, size-based sieving based on published protocols (33, 34) 
(see Supplementary Figures).  Average PT isolation efficiency and viability was assessed using 
hemocytometer cell counts as well as live-dead Hoechst and propidium iodine (PI) staining, 
respectively (see Supplementary Figures). PT isolation purity was verified using RT-PCR for 
known proximal tubule biomarker aquaporin 1 (AQP1), distal tubule marker aquaporin 2 (AQP2), 
and collective ducts (Na-Cl co-transporter (NCC)) (see Supplementary Figures) (33). The 
procedure yielded approximately 95,200±34,460 tubule fragments per kidney with 85±8% viability 
(n=3) at high isolate purity as verified by RT-PCR (see Supplementary Figures). 
Engineering congruent 3-D organoid proximal tubule constructs  
Organoid 3-D cultures were created by encapsulating intact murine (C56BL/6 mice) proximal 
tubule fragments within commercial biomedical-grade HA hydrogels. Importantly, PT cell viability in 
these 3-D organoid hydrogel constructs requires 1) gentle gel encapsulation conditions, 2) 
consistent diffusion of oxygen and nutrients throughout the gel-tubule construct, and 3) 
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miniaturized construct size and optimized geometry to facilitate nutrient transport. The 
thiol-modified HA covalently crosslinks to form a hydrogel spontaneously within the cell incubator 
when combined with PEG-diacrylate electrophile for ~35 min. Nine different HA formulations were 
evaluated for their ability to encapsulate PTs (see Supplementary Tables). HA formulation 
consisting of 1.5% CMHA-S-7.5% PEGDA was chosen due to relatively fast gelation and network 
stability during 2-month incubation in the cell culture hood. Each construct was formed by 50 µL of 
gel with PTs (the smallest technically feasible volume) to improve diffusion of oxygen and media. 
HA gels containing PTs were fabricated in polystyrene 96-well plates coated with TeflonAF® to 
reduce the wetting meniscus between the gel and plate wall, yielding symmetrical, uniform 
cylindrical gel constructs with roughly equal oxygenation gradients throughout the 3-D culture in 
the plate (Fig. 3.1A). Cell survival was analyzed in the meniscus zone at 1-week time points to 
verify that symmetrical gel constructs produced significantly less cell death than gel constructs 
with high menisci (data not shown). Furthermore, selected HA formulations produced a highly 
porous biopolymer gel matrix that accommodated encapsulated organoid oxygen delivery 
requirements, metabolite transport, and cell survival in culture with requisite integrity for up to 2 
months (Fig. 3.1B). 
Proximal tubule culture viability, differentiation, and functionality 
In addition to preservation of appropriate 3D tubule organization, HA constructs containing 
PTs were characterized for viability, differentiation, and functionality. Data for PT epithelial cell 





Figure 3.1 I Optimization of 96-well plates and gel formulation for 3-D organoid cultures. A) Profile 
of meniscus of polymerized HA hydrogels in TCPS microwell plates (left), and in 
TeflonAF®-coated non-TCPS microwell plates (right); B) SEM of the desiccated HA hydrogel 




























Figure 3.2 I Cellular characterization in 3-D organoid cultures during 2 months of incubation. A) 
Cell viability in proximal tubule fragments encapsulated by HA (n=3 (2 technical replicas), 
mean±SE), B) Senescence in the 3-D organoid culture (n=3 (2 technical replicas), mean±95%CI), 
C) RT-PCR for nephron markers: AQP1 - proximal tubule aquaporin, AQP2 - distal tubule 

















epithelial cells populated the 3-D organoid cultures for up to 2 months (Fig. 3.2A). Cell viability was 
evaluated at 5000 PTs/gel construct/well using CyQuant NF® assays, and at 3x10
4
 PTs per gel 
construct per well using MTS assays. Both assays are common approaches to evaluate cell 
viability in vitro. Different seeding densities were used to understand if the PT construct viability 
was limited by cell-to-gel ratio. Both assays were consistent in demonstrating that cell viability 
dropped two-fold in the PT constructs within the first 2 weeks, after which time it stabilized, 
reaching a plateau for the remainder of the culture period (Fig. 3.2A). Cell senescence was also 
evaluated (Fig. 3.2B) to test the hypothesis that the initial cell death in the 3-D organoid cultures 
was potentially the result of acute insufficient oxygen diffusion post-harvest. No increase in cell 
senescence in culture (Fig. 3.2B) was observed for 2 months. 
Although viability in 3D organoid cultures is a critical parameter, equally valuable for 
functional equivalence is the cell differentiation status. During the 2 months of culture, cell 
differentiation was gauged by RT-PCR and immunofluorescence assays. RT-PCR was performed 
bi-weekly using nephron-specific markers, AQP1, AQP2, NCC, and megalin, with the 
housekeeping gene, GAPDH. Proximal tubule-specific aquaporin (AQP1) and megalin but no 
other general nephron transcripts were found to be expressed in PTs encapsulated in the HA 
hydrogel for 2 months (Fig. 3.2C). Furthermore, these mRNA data were confirmed with 
immunofluorescence specific for AQP1 and Phaseolus vulgaris erythroagglutinin labeled with 
FITC (PHA-E) at 2 months (Fig. 3.3A,B). Differentiation markers for structurally important proximal 
tubule characteristics were further supported by continuous expression of cytochrome P450 




Figure 3.3 I Staining for cell differentiation markers: A) AQP1 staining after 2 months’ culture, B) 
PHA-E staining after 2 months’ culture, C) CYP2B1 staining after 2 months’ culture, D) CYP2E1 
staining after 2 months’ culture, E) gap junctions staining after 2 months’ culture, F) OAT1 staining 
after 2 months’ culture, G) α3 integrin staining after 2 months’ culture, H) PHA-E staining 2 days, I) 
CYP2E1 control well (no drugs) staining at 3 days, J) CYP2E1 staining after 1% acetone treatment 
















metabolically active, with CYP2E1 one of the most strongly expressed biotransformation enzymes 
(39). Although CYP2E1 protein is not present in the human kidney, it has been implicated in 
rodentproximal tubule cell damage associated with bioactive molecules and environmental agents 
(40). Overall, both immunofluorescence for differentiation markers and RT-PCR suggest that all 
cells that remained in the HA hydrogel for 2 months retained their differentiation status for the 
entire culture period.  
Proximal tubule epithelial cells phenotypic functionality inside PTs was evaluated as a series 
of enzymatic activity assays that tested their capability to process proteins from the media 
(cathepsin B (41)), maintain ligands for biotransformation (γ-glutamyl-transferase (42)) and 
endocytosis (megalin (27, 43, 44)), and continue signaling molecule dephosphorylation (alkaline 
phosphatase (AP) (45)). It was established that all measured enzymes, proteases, and ligands 
were present in cells over 6-8 weeks of culture (Fig. 3.2C, and 3.4A-C). Furthermore, it was 
confirmed that megalin ligand on the cell surface could assist in drug uptake similar to in vivo 
behavior in the presence of increasing gradients of the endocytosis inhibitor, colchicine (Fig. 3.4D).  
Another important difference between 2-D and in vivo proximal epithelial cell physiology is ability 
to oxidize lactic acid as a part of gluconeogenesis (46-49). Gluconeogenesis is a metabolic 
pathway that converts non-carbohydrate substrates, such as pyruvate, lactate and other 
non-glucidic precursors, into glucose. Specifically, immortalized proximal tubule-like cell lines lack 
gluconeogenic potential (47) and primary proximal tubule epithelial cells grown in static 2-D 
monolayer approach rapidly lose their gluconeogenic potential (49-51). Since gluconeogenesis is 
an important and distinctive feature of fully differentiated proximal tubule cells (52, 53), cellular 
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Figure 3.4 I  Enzyme expression in the 3-D organoid culture: A) cathepsin B ((n=3 (2 technical 
replicas), mean±95% CI), B) γ-glutamyl-transferase (n=3 (2 technical replicas), mean±95% CI), C) 
alkaline phosphatase (n=3 (2 technical replicas), mean±SE) D) neomycin endocytosis in the 
presence of endocytosis inhibitor colchicine  (n=3 (2 technical replicas), mean±SE), E) 


























































































































ability to oxidize one of the possible non-carbohydrate substrates, lactate, to glucose was 
assessed in the presence of phloridzin, an inhibitor of glucose transport across the apical cell side, 
and phloridzin with phloretin, an inhibitor of glucose transport across the basolateral membrane 
(49) (Fig. 3.4E). Addition of both inhibitors resulted in significant net glucose increases in 3-D 
cultures grown in the presence of lactate (Fig. 3.4E). 
Preservation of 3-D organoid cell organization 
A major objective of this study was to assess cell-cell and cell-matrix interactions and 3-D 
organization in preserving cultured cell phenotypic behaviors most consistent with in vivo traits. 
Specifically in the kidney, maintenance of both accessible luminal and basal epithelial cell 
membranes in PTs is critical in obtaining accurate in vivo-equivalent cell data, since both PT cell 
surfaces require direct accessibility to signaling stimuli through diffusion, transporters, and ligands. 
This is naturally limited in cell monocultures on plastic. Native PT microenvironment biomarkers 
assessed were gap junctions (connexin 43), integrins (α3), and cell polarization (transporter 
localization) using immunofluorescence assays. Antibodies against connexin 43, α3, and organic 
anion transporter 1 (OAT 1) revealed extensive labeling of epithelial PT cells after 2 months of 
culture within the HA gels (Fig. 3.3C-E). OAT 1 transporter was clearly associated with the basal 
side of PTs, suggesting that prolonged culture in 3-D HA gel did not affect cell polarization. 
Moreover, immunofluorescence using proximal tubule-specific lectin, PHA-E, indicated that PTs in 
the gel constructs maintained their tubular shape, with open lumens accessible to external stimuli 
(Fig. 3.3F) such as nutrients and drugs. 
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Culture responses to nephrotoxins; PT biomarker induction  
The 3-D culture’s capacity to respond to nephrotoxic agent exposures with toxicity indicators 
only measurable in vivo was determined by assessing its ability to up-regulate CYP P450 
enzymes and the Kim-1 protein in response to acetone and cisplatin, respectively. Antibody-based 
staining for CYP2E1 (Fig. 3.3 I,J) and Kim-1 (Fig. 3.3 K,L) in response to acetone and cisplatin 
showed presence of both biomarkers in the tested conditions.   
Culture response to nephrotoxins: drug metabolite production 
Cisplatin toxicity in vivo is at least partially attributed to formation of metabolites in the PT 
epithelial cells (54-58). To assess the 3-D culture’s ability to process drugs similarly to that 
reported in vivo, metabolite production was assessed in the media and cytosol of PTs in 
protein-free media after 1h (see Supplemental Figures) and 6h (see Supplemental Figures) of 
incubation with cisplatin. In 3-D organoid cultures collected, protein-free PT media contained 





, peak E), and cisplatin- N-acetylcysteine (NAC, peaks F,G). Cytosol of the cells 
had the above peaks as well as peaks A and C. Peak A eluted at the same time as cisplatin- 
glutathione (GSH) and cisplatin-cysteine (Cys), and peak C had similar retention times to 
cisptain-NAC and cisplatin-Cys-Gly.   
Culture response to nephrotoxins: inflammatory protein production 
Pro-inflammatory soluble proteins TNFα, MCP-1, IL-6, IL-1β, MIP-1α, and RANTES were 
measured after 3 days of exposure to nephrotoxic drugs to evaluate 3-D culture’s ability to elicit 
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immune response. Nephrotoxic compounds, cisplatin and doxorubicin, 4-aminophenol (PAP), and 
colchicine exhibited significant up-regulation of IL-6 and MCP-1 with all drug exposures, RANTES 
and MIP-1α for all drugs except PAP, and IL-1β for cisplatin and doxorubicin only (Figure 3.5).  
Discussion 
Nephrotoxicity is a complex pathology that combines tissue damage through interference 
with biochemical, metabolic, and nuclear processes. Furthermore, this form of toxicity has poor 
structure-toxicity predictions, making nephrotoxicity almost an idiosyncratic occurrence in clinical 
drug use. Hence, its prediction by oversimplified systems, such as immortalized cell lines that lack 
important structural elements or are limited in their ability to respond with physiologically-relevant 
indicators, is highly compromised and unreliable. For example, most transformed cells are missing 
OAT (1-3), organic cation (OCT 1-2), peptide (PEPT 1-2), and P-glycoprotein transporters critical 
for drug accumulation in cells, have poor levels of AP and γ-glutamyl-transferase that play roles in 
cell signaling and drug biotransformation. Additionally, transformed cells express different native 
tissue adhesion molecules such as E-cadherin instead of N-cadherin critical in chemical and 
mechanical sensing of intracellular and cell-ECM bi-directional signal transduction, and lack or 
exhibit limited morphological features such as microvilli, tight junctions, and ligands important in 
the development of cellular pathologies in vivo. This lack of ability to sense and respond to cellular 
microenvironmental cues unsurprisingly results in significant differences in cell damage biomarker 
induction. Specifically, no immortalized cell lines have been reported to induce Kim-1 protein, the 






















































































































Figure 3.5 I Inflammatory cytokine release into culture media at drugs’ EC50 values: doxorubicin 





with toxicity, or produce extensive paracrine cytokine production in response to chemical 
injury.Therefore, use of primary cells in a culture environment that supports their native 
interactions and retains their tissue-like differentiation state is critical for producing in vitro models 
capable of clinically relevant toxicological data collection. 
Our design combines now-routine tissue engineering approaches for 3-D scaffold-supported 
cell culture with highly accepted and validated use of isolated PT harvests (33, 34) to validate a 
new 3-D organoid PT culture system that preserves PT tubule epithelial cell functions and 
phenotypes for several months (18). The protocol to isolate proximal tubule-enriched 
subpopulations from freshly harvested intact C57BL/6 murine kidneys was reliable and efficient, 
which was verified by staining (see Supplementary Figures) as well as RT-PCR for known nephron 
biomarkers (see Supplementary Figures) (33). Isolated PTs were sustained in culture using 
biomedical-grade HA polymer that was previously used to differentiate and maintain multiple 
different cell types. As a natural glycan-based biopolymer found in most human tissues, 
commercial HA-derived hydrogel recognized for its mild gelation conditions, cell and tissue 
compatibility due to its compatibility with soft tissues’ elastic modulus (similar formulation was 
found to have G’ of 3500 Pa) (35) and high network porosity (large mesh size). This thiol-modified 
HA covalently crosslinks to form a hydrogel spontaneously within the cell incubator at physiological 
pH and without harmful chemistry. Nine different HA formulations with varying thiol concentrations, 
molecular weights of co-added PEG-acrylate electrophile, and HA thiol:PEGacrylate ratios were 
evaluated for their ability to encapsulate PTs (see Supplementary Tables). Changing these matrix 
variables resulted in different gel network porosities, stabilities, stiffnesses, and gelation times. HA 
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gels comprising 1.5% CMHA-S-7.5% PEGDA were chosen due to relatively fast gelation (35 min) 
and network stability during prolonged incubation. This selected HA formulation allowed the 
maintaintenance of PTs inside of the gel in their native tubular shape with open lumens, which was 
verified both by immunohistochemistry (Fig. 3.3F) and ability of nephrotoxic drugs to gain access 
to the proximal epithelial cells inside of PTs (Fig. 3.4D). The smallest technically feasible volume of 
this HA biopolymer was mixed directly with PT harvests to form encapsulated cell constructs with 
diffusion accessibility for oxygen and media. In vivo, the average distance between blood vessels 
carrying oxygen and cells that consume it is 150-200 nm (59). Lack of blood vessels and technical 
complexity of making 3-D cultures with mm thickness, including the 3-D organoid culture 
presented here, remains one of the primary challenges of the field. In this work cell viability 
dropped two-fold in the PT constructs within the first 2 weeks (Fig. 2A) most likely due to cell death 
as a result insufficient oxygen in the deepest gel layers in the plates. In future studies, cell viability 
in the 3-D organoid cultures may be improved using active perfusion rather than static 
diffusion-limited cultures. 
Despite the imperfect diffusion of oxygen throughout the culture, the 3-D organoid PT 
constructs in their native environment proved to retain markers of cellular differentiation, such as 
AQP1 and megalin expression in PTs and histological staining with PHA-E, for 2 months of 
construct culturing in vitro (Fig. 3.2C and 3.3A,B). Similarly, biomarkers that reflect conservation of 
intracellular connections, such as gap junctions and integrins, and cellular polarization were 
sustained for the same amount of time within the HA gels (Fig. 3.3C-E). Furthermore, the epithelial 
proximal tubule cells that line PTs proved to be able to oxidize lactic acid to glucose proving to 
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maintain more in vivo-like rather then 2-D cell culture properties (Fig. 3.4E). In vivo, proximal 
tubule cells generate their energy primarily through oxidative metabolism, converting 
non-carbohydrate substrates such as lactate into glucose (48, 60-62). In vitro, cells cultured using 
traditional monolayer approaches suffer from reduction of gluconeogenesis and even complete 
reversal to glycolysis (49). Previous data show metabolic reversal in 2-D cell monolayers as a 
result of hypoxia and high glucose concentrations in the culture media (49, 53, 63, 64). Organoid 
cultures were assayed for glucose net production in the media in the presence of phloridzin, an 
inhibitor of glucose transport across the apical cell side (49), and phloridzin with ploretin, an 
inhibitor of glucose transport across the basolateral membrane (49) (Fig. 3.4E). Both inhibitors 
elicited significant net glucose increases in proximal tubule 3-D cultures grown in the presence of 
lactate, indicating important retention of glucose conversion and up-take mechanisms in 3-D 
organoid cultures. These data further indicate that primary proximal tubule epithelial cells in the 
3-D proximal tubule organoid cultures maintain metabolic profiles similar to cells in vivo. 
Retention of cellular architecture, organization, and gluconeogenic potential in vitro in the 3-D 
organoid cultures were accompanied by maintenance of proximal tubule epithelial cells’ 
phenotypic functionality. Specifically, cells conserved structural capability to process proteins from 
the media via cathepsin B (41), maintained enzymes involved in drug biotransformation 
(γ-glutamyl-transferase (42)) and endocytosis (megalin (27, 43, 44)), and retained proteins that 
are responsible for  signaling molecule dephosphorylation (AP (45)). Cathepsin B is a protease 
critical for lysosomal protein degradation in normal protein metabolism (41). AP is a brush border 
enzyme essential for cell signaling (41, 45). Megalin is a cell ligand that extracts proteins such as 
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albumin from the glomerular filtrate and transports them back into proximal tubule epithelial cells 
for re-absorption or degradation (65). γ-glutamyl-transferase is an enzyme located on proximal 
tubule microvilli responsible for amino acid uptake (42). Besides functions associated with normal 
PT cell physiology, megalin and γ-glutamyl-transferase are also implicated in drug transport and 
biotransformation in the proximal tubule epithelial cells (19, 66). It was established that all 
measured enzymes, proteases, and ligands were present in cells over 6-8 weeks of culture (Fig. 
3.2C, and 3.4A-C). Furthermore, it was confirmed that megalin ligand on the cell surface could 
assist in drug uptake similar to in vivo behavior. To achieve this, proximal tubule 3-D organoid 
constructs were exposed to neomycin, a toxic aminoglycoside drug well-known to enter PT cells 
via interaction with megalin (67), in the presence of increasing gradients of the endocytosis 
inhibitor, colchicine. As expected, decreased neomycin accumulation in cells due to abrogated 
endocytosis resulted in reduced cell death in the 3-D organoid culture, further supporting the 
proposal that these culture conditions support functional PT epithelial cells (Fig. 3.4D). These data 
cumulatively suggest that preservation of native microenvironment leads to significant 
improvements in cells’ long-term functionality maintenance in vitro.  
To capitalize on advances of the developed 3-D organoid culture, cellular capacity to respond 
to nephrotoxic agent exposures with toxicity indicators only measurable in vivo was determined. 
Specifically, 3-D cultures’ ability to up-regulate CYP P450 enzymes and Kim-1 protein in response 
to known nephrotoxins, acetone (40, 68) and cisplatin (69, 70), was assessed. Cytochrome 
CYP2E1 was chosen because it is one of the most abundantly expressed enzymes in murine 
kidneys and a common target for exogenous agent detoxification (39). Furthermore, in vivo 
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acetone induces nephrotoxicity in rodents and is also a well-established substrate for CYP2E1 
biotransformation (39). Similarly, Kim-1 is one of the most sensitive markers of nephrotoxicity and 
commonly used as a hallmark of general kidney injury in vivo (71). Kim-1 up-regulation in 
response to cisplatin-induced toxicity is a well-characterized phenomenon in both rodents and 
humans (70, 72). Cisplatin, a potent chemotherapeutic drug limited in clinical use by severe PT 
toxicity (73), was applied to the 3-D organoid culture in this work at a concentration corresponding 
to the common mouse clinical dose (20 mg/kg) that causes kidney damage in mice in 3 days to 
ensure more relevant in vivo-to-in vitro comparison (73). Positive staining for CYP2E1 (Fig. 3.3 I,J) 
and Kim-1 (Fig. 3.3 K,L) in response to acetone and cisplatin, respectively, confirmed previously 
published whole animal nephrotoxicity data and ascertained 3-D organoid culture’s ability to 
respond to endogenous toxicants with in vivo-relevant biomarkers.  
Validation of the improved predictive power of the 3-D PT organoid culture is required to 
assert its relevance to predicting clinically important outcomes. In this work production of drug’s 
metabolites was assessed using previously published protocols on the example of cisplatin (see 
Supplemental Figures). Seven platinum-containing metabolized chemical species were previously 
reported in rodent kidneys (56, 58), from which cisplatin adducts with glutathione (GSH), 
N-acetylcysteine (NAC), and cysteinyl-glycine (Cys-Gly) were reported to be toxic to cells in vitro 





, peak E), and cisplatin-NAC (peaks 
F,G) in the proximal tubule media, and additional peaks A and C in the harvested cytosol. 
Comparing 3-D culture elution peaks with standards for drug-enzyme incubations, peak A eluted at 
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the same time as cisplatin-GSH and cisplatin-cysteine, and peak C had similar retention times to 
cisptain-NAC and cisplatin-Cys-Gly. These data indicate that primary proximal tubule cells cultured 
in their native proximal tubule environment are capable of transforming a drug as expected in vivo.   
Besides drug-specific detoxification pathways in the kidneys, 3-D organoid cultures were 
assessed for ability to induce pro-inflammatory events associated with toxicity leading to acute 
kidney injury (AKI) (3). Several studies have suggested that in vivo initial insult on PT epithelium 
sets up a cascade of events that produces morphological and molecular changes in the kidney, 
resulting in production of cytokines and chemokines that attract macrophages, natural killer cells, 
neutrophils, and leukocytes to the site of injury. In the nephrotoxic model of AKI, TNFα, MCP-1, 
IL-6, IL-1β, MIP-1α, and RANTES proteins are mediators of inflammation that are either released 
or regulated by epithelial cells (3). In this work, IL-6, TNF, MCP-1, IL-1β, MIP-1α, and RANTES 
secretion by primary cells was tested in response to common clinically used nephrotoxic drugs, 
cisplatin and doxorubicin, drug metabolite PAP, and suspected nephrotoxin, colchicine. After 3-day 
incubations with each drug, the 3-D culture model exhibited significant up-regulation of IL-6 and 
MCP-1 with all drug exposures, RANTES and MIP-1α for all drugs except PAP, and IL-1β for 
cisplatin and doxorubicin only (Figure 3.5). These data matched well to cytokine profiles 
associated with nephrotoxicity in AKI models (3). For example, TNFα, unlike all other inflammatory 
proteins tested here, is up-regulated but is not cleaved from the epithelial surface, and hence not 
commonly found in the urine in vivo (74). In this work, TNFα release into the media was not 
significant for any drugs, similar to published animal data. Furthermore, cisplatin-induced protein 
induction of TNFα, IL-1β, MCP-1, IL-6 and RANTES corresponded directly to an in vivo model of 
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cisplatin-induced AKI (75). In addition to the cytokines and chemokines listed (vida supra), MIP-1α 
was found to be significantly increased in 3-D cell cultures exposed to cisplatin. Although MIP-1α 
has not been specifically studied in association with the drug, it is a ligand that binds to the same 
receptor as RANTES in the ischemic model of AKI and has been previously shown to be 
up-regulated together with MCP-1 under regulation of IL-1β in proximal epithelial cells (3, 76). 
Hence, MCP-1 is a likely chemokine candidate in the cisplatin model of AKI. Taken together, these 
data collectively point to significant similarities in cytokine and chemokine production between in 
vivo and the in vitro 3-D organoid endpoints of drug toxicity. 
Presented data on functional equivalency between the 3-D organoid culture and in vivo 
available information from the literature confirm the hypothesis that preservation of native cellular 
microenvironment that houses PT epithelial cells within their endogenous matrix, sustaining the 
native cell-cell, cell-matrix, and biochemical cues, while limiting non-native cell-polymer 
interactions and 2-D culture artifacts, better retains essential cellular responses relevant to in vivo 
kidney pathophysiology. This ‘proof of concept’ has answered fundamental questions about the 
role of the primary cell microenvironment on cell long-term viability, differentiation stability, and 
contextual functionality of cells in an in vitro culture system. Furthermore, the study provides 
important value as support for the future potential of such in vitro culture designs in replicating the 
necessary physiological features for more accurately predicting in vivo-like processes. This 
includes the ability of these organoid cultures to respond to environmental stimuli with clinically 





The 3-D organoid culture developed in this study provides the technical capability to sustain 
the complex nature of primary cell interactions during prolonged culture conditions by manipulating 
a cell’s direct, natural microenvironment. By preserving native cell organization and intracellular 
interactions in organoid harvests, no re-introduction of such tissue complexity needs to be built 
back into a 3-D culture system or fabricated de novo. The PT primary epithelial cells retain their 
natural contextual environment as found in vivo, and therefore their extended in vitro culture 
sustains and extends cell phenotypic and functional stability for almost 2 months. This method 
should provide a platform for improved assessment and validation of kidney-related disease and 
toxicity biomarkers for HTS 96-well screening, as well as serve as a model for basic molecular 
biology studies in drug-drug interactions, drug-induced toxicity, and metabolism. Additionally, 
further exploration using the 3-D organoid model may provide insight that would lead to greater 
understanding of cell organizational and communication roles in tissue functional maintenance. 
This level of understanding further informs the design parameters for improved bioreactor models 
for 3-D cell scaffolds popular in regenerative medicine and tissue engineering. The model should 
also facilitate establishment of cell culture models better suited to directly assess and contrast 
different in vivo and in vitro pathophysiology and tissue damage biomarkers. 
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1 high 3350 16 16 1.26 : 1 
2 high 3350 16 20 1 : 1 
3 high 6000 16 16 2.26 : 1 
4 high 6000 16 36 1 : 1 
5 low 3350 20 10 1 : 1 
6 low 6000 20 18 1 : 1 
7 high 3350 8 10 1 : 1 
8 high 3350 12 15 1 : 1 













































































































Supplementary Figure 3.2 Isolation purity of proximal tubules. A) Isolated proximal tubule 
fragments stained with PI and Hoechst for assessment of live and dead cells in PTs; B) PCR 
results for nephron markers showing high yield of proximal tubule isolation procedure: 









 Supplementary Figure 3.3 Cisplatin metabolite production in 3-D organoid proximal tubule culture in: A) media after 1 hour of incubation with the 
drug, B) epithelial cell cytosol after 1h incubation with the drug, C) media after 6h incubation with the drug, D) epithelial cell cytosol after 6h 









INFLUENCE OF DRUG HYDROPHOBICITY, CELL CONFLUENCE, AND ASSAY SELECTION 
ON TOXICITY ASSESSMENT IN VITRO IN PRIMARY AND  




Primary and immortalized kidney cell lines are used interchangeably in the scientific literature 
for toxicity assessment of pharmaceutical agents, drug delivery vehicles, and biomaterials without 
much reported validation of their fidelity to each other or to actual in vivo cell responses. Two 
immortalized kidney-derived cell lines (HEK293 cells and LLC-PK1), each with different 
phenotypes resembling epithelial cells, were compared in drug toxicity assays. Results were shown 
to vary widely based on incubation time, drug partition coefficient, culture confluence, and viability 
assays. Specifically, immortalized cell lines showed non-monotonic dose response curve 
(NMDRC) toxicity behavior for hydrophobic but not hydrophilic drugs, when tested on cultures at 
low cell seeding densities, at early time points of drug exposure, and different viability assessment 
assays. Unlike transformed kidney cell lines, primary kidney epithelial cells in 3-D hydrogel cultures 
produced in vivo-like dose-toxicity relationships to the same drugs. Collective data indicate that 
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only primary cell cultures should be used in this context for reliable in vivo-relevant toxicity 
screening that recapitulates key aspects of cell behaviors in vivo.  
Introduction 
 The majority of lead compound identification, drug delivery vehicle optimization, or drug 
discovery target validation is accomplished using cell-based in vitro assays both in industry and 
academia. Such assays can serve to measure drug-cell permeability routes and transport kinetics 
as well as dose-response relationships in toxicity studies. Use of both primary and immortalized 
cell lines is quite common, often applied interchangeably, based on the presumption that data 
collected from either cell type are physiologically relevant to in vivo cellular responses. Historically, 
use of immortalized or transformed cell lines has been the preferred method of drug development 
and screening (1, 2). The approach can be explained by convenience, ease-of-use, as well as 
reproducibility of data between different laboratories (1, 2). Specifically, transformed cell lines are 
readily sourced, easily expanded using common culture conditions, maintained in culture for 40-50 
generations, and readily handled in high through-put screening (HTS) methods using automation 
and robotic dispensing (2). In contrast, primary cells de-differentiate in vitro in days or weeks 
depending on the complexity of the native phenotype, are costly, tedious, and ethically challenging 
to extract from living tissue sources using a diverse array of tissue-specific cell isolation protocols, 
with resulting heterogeneous cell populations. Inherent difficulties associated with maintaining 
primary cell cultures often outweigh the disadvantages of using transformed cell lines. The 




multiple passaging produce distinct cellular differences compared to their native source (1). 
Genetic transformation is often achieved to increase culture convenience, at the expense of losing 
molecular, structural, and biochemical cell identifiers, resulting in reduced or completely altered 
processes in these cells and overall functional non-equivalence between the immortalized and in 
vivo cells (3-14). Hence, careful characterization of cellular behaviors, phenotypes, and specific 
processes relevant to those under investigation is required prior to model selection. Lack of 
validation and understanding of a cell culture model’s limitations makes interpretation of results 
and their physiological relevance highly tentative and possibly irreproducible.     
Nonetheless, transformed cell lines remain an important scientific tool for studies on drug 
receptors and transporters, ligand-substrate binding, and drug signaling pathways, where 
expression of all key molecular components for a particular study are controlled using targeted 
transfection or siRNA techniques to create specific mutations (1, 2). However, a growing body of 
literature reflects the limitations of these systems in providing accurate, reliable insight into highly 
complex and poorly understood physiological processes such as pharmacological studies (15-18), 
inflammation (16, 19-21), and cell signaling (22-25) in response to environmental stimuli. Often, a 
simplistic monocultured cell model, despite controlled phenotypic features, cannot reflect the 
complexity of host physiology in drug-tissue interactions, pharmacokinetics, pharmacodynamics, 
metabolic processing, toxicity, and therapy. Their use in pharmacological and toxicological 
translation is often presumed, empirically determined and often unrealiable. 
Assessing kidney toxicity (nephrotoxicity) of exogenous agents likely succumbs to this 




that line proximal tubules (PTs) in the kidney nephron (26). PT toxicity is a cumulative 
compounding sequence of events that includes drug accumulation, biotransformation, and 
apoptosis induction. PT drug uptake is achieved via drug-specific active transporters (i.e., organic 
cation transporter 2 (OCT2) for cisplatin (27), P-glycoprotein for doxorubicin (28) and colchicine 
(29)), ligands (e.g., megalin for aminoglycoside drugs (7)) and microvilli surface area-assisted 
passive diffusion. Drug biotransformation occurs as a series of biochemical interactions with brush 
border enzymes (e.g., γ-glutamyl-transferase for cisplatin (27)), intracellular enzymes (i.e., 
glutathione for cisplatin (27)) and P450 cytochromes (27, 30). The active metabolites of 
biotransformation, protein-drug conjugates, and free drug accumulated in the cytoplasm then 
initiate cellular apoptosis and necrosis. All of these components play a compound, complex role to 
induce nephrotoxicity, and, hence, their functional preservation in vitro in culture is critical to 
achieve kidney toxicology assays with any relevance to in vivo nephrotoxicity.  
Basic studies of different immortalized kidney cells lines in vitro support a current, clear 
understanding that transformed cell lines lack clinically relevant markers such as toxicity-related 
gene up-regulation, ion-sensing receptors that serve as drug agonists, endocytic scavenger 
receptors implicated in drug uptake and early injury, biosynthesis of drug metabolizing enzymes, 
and Toll-like receptors mediating inflammation in drug toxicity (3-9, 31). Hence, immortalized 
kidney cell lines would likely be intrinsically incapable of producing in vivo-relevant toxicity 
responses. Yet after decades, validation of their utility and accuracy in such nephrotoxicity 




This study compares immortalized kidney cell lines to differentially stable primary proximal 
tubule cell cultures in cellular toxicity studies using known drugs with different pharmacological 
indications and formulations but importantly, known nephrotoxicity in vivo. Furthermore, these cell 
toxicity data were collected as a function of exposure (incubation times) and cell densities 
commonly used in the literature and replicated using different assessment methodologies. Results 
show similar toxicity profiles between primary and immortalized cell lines for highly water-soluble 
drugs. However, almost any toxicity endpoint could be achieved with hydrophobic drugs and 




Drugs except for rifampicin and ciprofloxacin were purchased from Sigma-Aldrich Chemical 
Co. (St. Louis, USA). Ciproflaxin and rifampicin were purchased from LKT Laboratories, Inc. (St. 
Paul, USA) and Gold Biotechnology Co. (St. Louis, USA), respectively. Doxorubicin (doxorubicin 
hydrochloride, Sigma 44584), colchicine (Sigma C9754), dexamethasone (Sigma D4902), 
neomycin (neomycin trisulfate salt hydrate, Sigma N6386), rifampicin (LKT R3220), ciprofloxacin 
(LKT C3262) were dissolved in dimethyl sulfoxide (DMSO) (Fisher Scientific) as 20 or 200mM 






Immortalized cell resources and cell culture  
Porcine secondary LLC-PK1 renal proximal tubule epithelial cells were purchased from 
ATCC (Manassas, USA). Human secondary HEK293 renal proximal tubule epithelial cells were 
generously donated by Dr. A. Cheung, University of Utah. Cell lines were expanded using aseptic 
techniques in DMEM (Invitrogen, USA) with 10% FBS (Invitrogen) and 1% anti-anti (Invitrogen). 
Both cell lines were kept in cell culture incubator with 5% CO2 and 95% air at 37°C. 
For all experiments, cells were seeded in 96-well tissue culture plates (Fisher Scientific, USA) 
at either 170,750 cells/well or 10,000 cells/well concentrations and allowed to adhere for 2 hours 
using DMEM media with 10% FBS. Cultures with lower cell numbers were used to assess 
inter-epithelial transport in the uptake of drugs (see Supplemental Figures). Higher cell numbers 
were chosen to create monolayer-like cultures (see Supplemental Figures).  All drugs were 
diluted to their final concentrations (except for the no-FCS control experiment) in proximal tubule 
complete media (1% FCS, 5% sodium pyruvate, 1% non-essential amino acids, 1% 
insulin/transferrin/selenium, 1% anti-anti, 0.9 µg of hydrocortisone, phenol red-free DMEM-Ham's 
F-12 with L-glutamine) and sterilized using 0.22µm pore filtration. Experiments without growth 
factors used incomplete PT media (5% sodium pyruvate, 1% non-essential amino acids, 1% 
insulin/transferrin/selenium, 1% anti-anti, 0.9 µg of hydrocortisone, phenol red-free DMEM-Ham's 
F-12 with L-glutamine). Phenol red-free media was used in all experiments to avoid optical 






3-D organoid constructs preparation   
All 3-D constructs were made using Teflon-AF® (Dupont)-coated non-tissue culture 
polystyrene plates (ISC Bioexpress, USA). Teflon-AF® was resuspended in FC-40 (3M, USA) 
organic solvent and applied to culture surfaces per previously published protocols (32, 33). 
Solvent was removed using heated vacuum drying. Plates were sterilized using UV irradiation in  
the cell culture hood for 30 min before use. All 3-D cultures were made using primary PTs from 
male C57BL/6 mice 6-8 weeks old that were purchased from Jackson Laboratory (Bar Harbor, 
USA). PTs were isolated according to our lab’s published method (32). Briefly, isolated kidneys 
were prepared by removal of kidney capsule, blood vessels, and ureter using standard aseptic 
conditions in BSL2 laminar flow hood. Tissues were finely mechanically disrupted and 
enzymatically digested in collagenase IV (Worthington Biochemical Corporation, USA), DNAse I 
(Sigma-Aldrich, USA), and HAse (Worthington Biochemical Corporation,USA) enzyme KREBS 
solution (145 mM NaCl, 10 mM HEPES, 5 mM KCl, 1 mM NaH2PO4, 2.5 mM CaCl2, 1.8 mM 
MgSO4, 5 mM glucose, pH 7.3) at 37
ᵒ
C (34). Digested sections of the kidney were put through a 
series 80 µM and 250 µM of sieves (35). The resulting suspension of PTs resuspended in 1.5% 
thiol-modified carboxymethylated HA (CMHA-S, Sentrx Animal Care, Salt Lake City, USA) in 
PBS
++
, and cross-linked using 7.5% poly(ethylene glycol) diacrylate (PEGDA) bifunctional 
electrophile (4:1 v/v CMHA-S:PEGDA, total volume 50 µL, SentrX Animal Care, Salt Lake City, 
USA) into 3-D constructs (36). Crosslinking was done for 35 min in the incubator followed by full 




after preparation. The constructs were maintained in the incubator with 5% CO2 with culture media 
exchanged every other day for optimum viability. 
Cytotoxicity measurements  
Cytotoxicity due to various chemicals in LLC-PK1 and HEK293 cells was assessed using the 
DNA-labeling assay, CyQuant NF® (Invitrogen, USA); necrosis measured using the ToxiLight® 
(Lonza, USA) assay, and the metabolic MTS assay (Fisher, USA). Linear assay responses were 
verified using standard curves (see Supplemental Figures). All cell lysis standard curves for 
ToxiLight® assays were determined for each time point using ToxiLight® 100% Lysis Reagent Set 
(Lonza, USA). All assays were performed in triplicate using two technical replicas in each 
experiment. 
After incubating drug solutions for the indicated culture periods, cells and media were 
separated for further analysis. Cells were assessed for cell viability using MTS or CyQuant NF®. 
Media from the cells was assayed for cell necrosis using ToxiLight®. For MTS assays, MTS 
reagent was diluted according to manufacturer’s instructions and stored at -20°C. Prior to cell 
exposure, 20µL of defrosted MTS reagent was mixed with 100µL of PT complete media for each 
tested well. Cells were incubated with final media-diluted reagent for 1 hour in the incubator. For 
CyQuant NF®, cells were exposed to 100µL of dye prepared according to manufacture’s 
instructions for 1 hour in the cell culture incubator. For ToxiLight®, 20µL of cell media was 
transferred to opaque 96-well plates (Dynex Microlite, USA), cooled at room temperature (RT) for 




fluorescence (using 485nm excitation and 529nm emission wavelengths, respectively), MTS 
absorbance (490nm) and ToxiLight® luminescence were measured using a Synergy 2 plate 
reader (BioTek, USA). CyQuant NF® and MTS data were expressed as a percent of cell survival 
through normalization to wells containing cells not exposed to any drugs, and ToxiLight® data 
were expressed as percent cell death compared to 100% cell lysis as measured by ToxiLight® 
100% Lysis Reagent Set. 
Drug aggregation assay in culture media 
Colchicine aggregation in PT complete media was assessed using a Nano-ZS Zetasizer 
(Malvern Instruments, USA). Final drug concentrations in the PT complete media were incubated 
at RT in a 96-well tissue culture polystyrene plate. Drug aggregation detected as particle formation 
in the media was assessed at 2 hours for colchicine, rifampicin, dexamethasone, and ciprofloxacin 
and every 20 min for 3-hours for colchicine (see Supplemental Tables). 
Statistical analyses  
All data analysis was performed using Excel 2010 (Microsoft) and GraphPad Prism 5 
(GraphPad Software, Inc., USA). All cell experiments were performed using three independent 
samples with two technical replicas.  All data in the paper were presented as mean±S.E 
(standard error). Significant differences in binary comparisons were determined using one–way 







Drug effects on cell viability as a function of cell assay  
Three common commercial cells assays -- CyQuant NF®, MTS, and ToxiLight® -- were used 
to assess cell viability as an indicator of toxicity in vitro. For all time points tested, CyQuant NF® 
and ToxiLight® were found to be significantly more sensitive at detecting drug-induced damage 
than MTS. Specifically, MTS was able to detect cell death in culture, but failed to distinguish 
celldeath changes below 10% mortality from either doxorubicin and colchicine at most measured 
time points (likely confounded by these assays’ intrinsic lack of sensitivity at low percent cell 
death). Increasing the incubation time from 3 hours to 3 days did not change this trend, showing 
little cell damage due to exposure to both drugs (Figures 4.1 and 4.2). Furthermore, the 
luminescence-based necrosis assay, ToxiLight®, was shown to be highly susceptible to presence 
of residual organic solvent, DMSO, used in the drug stock solutions. Presence of DMSO above 
5% in solutions tested reduced assay luminescence signal by more than 10-fold (data not shown). 
Hence, all data presented for ToxiLight® assays used 0.5%-2% DMSO final concentrations with 
cells. Furthermore, continuously releasing substrate assays, such as ToxiLight®, lose their ability 
to discern between the 100% cell lysis as measured by ToxiLight® 100% Lysis Reagent Set and 
cell death due to drug exposure as a function of time. Both HEK293 and LLC-PK1 cells dropped 
from 5-fold to less than 2-fold in ToxiLight® assay sensitivity between 3 hours and 48 hours of cell 
incubation (Figure 4.3). Unlike ToxiLight® and MTS assays, CyQuantNF® assays seemed to be 





























































Figure 4.1. MTS cell viability assay from continuous incubation of HEK293 and LLC-PK1 cells with 
increased concentrations of colchicine: (A) 3 hours, (B) 24 hours, (C) 48 hours of incubation, and 


































































Figure 4.2. MTS cell viability assay for continuous incubation of HEK293 and LLC-PK1 cells with 
increasing concentrations of doxorubicin in cell culture media: (A) 3 hours, (B) 24 hours, (C) 48 

































Figure 4.3. Loss of ToxiLight® assay sensitivity with prolonged cell incubation: (A) HEK293 cells 

















time points. Furthermore, this assay was not confounded by drugs’ intrinsic fluorescent signatures 
or optical density (see Supplemental Figures).  
Drug effects on cell viability as a function of incubation time 
Drug toxicity using CyQuant NF®, MTS, and ToxiLight® assays were measured after 3 hours, 
6 hours, 24 hours, 48 hours, and 72 hours of drug incubation with HEK293 and LLC-PK1 cells 
using 170,750 cell/well seeding density. MTS assays detected no changes in cell viability at most 
measured time points and for all tested chemical agents (Figures 4.1 and 4.2). CyQuant NF® and 
ToxiLight® assays showed an expected trend of higher cell survival at lower doxorubicin 
hydrochloride and neomycin trisulfate salt hydrate concentrations at all tested time points. Within 
the first 3 hours of incubation, both drugs produced discernable changes in cell viability as a 
function of drug concentration. Differences in cell viability did not change significantly for the entire 
3 days of culture, although cell recovery was noticeable after 6 hours of cell incubation with 
doxorubicin and neomycin salts (Figure 4.4). These data matched previously in vitro published 
observations (37). In contrast to incubation with doxorubicin and neomycin salts, both CyQuant 
NF® and ToxiLight® assays detected increased cell survival at high colchicine concentrations and 
low cell survival at low colchicine concentrations at 3 hours for HEK293 and both 3 and 6 hours for 
LLC-PK1 cells (Figure 4.5). This observation was reversed with increasing incubation time. 
Notably, this toxicity-dose inversion occurs in a gradient manner for both cell lines tested by these 
two assays. Colchicine exposure of 24 hours was required with both HEK293 and LLC-PK1 cells 































































Figure 4.4. CyQuant NF® cell toxicity assay of HEK293 and LLC-PK1 cells with doxorubicin and 
neomycin drugs showing expected dose-dependent high drug concentration-low cell survival: (A) 
doxorubicin, 3 hours, (B) doxorubicin, 72 hours, (C) neomycin, 3 hours, and (D) neomycin, 24 




































Figure 4.5. HEK293 cell viability after 3 hour incubations with colchicine showing increased cell 
viability at higher drug concentrations measured using (A) CyQuant NF® (% cell survival) and (B) 


















effect was specific to colchicine, both immortalized cell lines were also exposed to rifampicin and 
ciprofloxacin. Rifampicin showed a “normal” toxicity relationship (i.e., increasing dose produces 
corresponding increases in toxicity), whereas ciprofloxacin exhibited a non-monotonic dose 
response curve (NMDRC (38)) for toxicity, similar also to that from colchicine, for all cell types and 
all time points tested (Figure 4.6). Primary PT cell cultures exposed to colchicine, dexamethasone, 
and ciprofloxacin produced the expected normal toxicity curves where increased cell death was  
observed at higher drug concentrations for all time points tested (Figure 4.7). 
Drug aggregation studies in media  
Aggregation kinetics for colchicine, rifampicin, dexamethasone, and ciprofloxacin in 
protein-containing cell culture media were explored after 2 hours of incubation. This exploited a 
commercial Zetasizer instrument capable of detecting particles as small as 4nm in diameter as a 
standard approach to assessing particle sizes and size distributions in solute environments. 
Additionally, colchicine was evaluated every 20 min for 2 hours (corresponding to the first 
measured cell toxicity time point). No drug aggregation was detected in all samples tested (see 
Supplemental Tables). 
Facilitated drug-cell permeation studies  
To assess whether the observed lack of cell response to drugs at high concentration in 
culture resulted from limited drug penetration, cell experiments were repeated using increased 
amounts of DMSO added to media. DMSO is known to increase drug permeation into cells (39). 


































Figure 4.6. CyQuant NF® assay of cell line culture viability treated with (A) ciprofloxacin and (B) 





























































Figure 4.7. Viability of primary proximal tubule cells with increasing concentrations of drugs in the 
culture media as measured by CyQuantNF®:(A) colchicine after 6 hours, (B) ciprofloxacin after 24 
hours, and (C) doxorubicin after 72 hours of incubation. See data in Supplemental Figures 








viability in control cells (i.e., cells exposed to no drug) (see Supplemental Figures). Due to DMSO 
interference with the ToxiLight® assay and lack of sensitivity associated with the MTS assay, all 
experiments were performed using the CyQuant NF® assays against new standard curves run in 
the presence of DMSO. Increased DMSO fractions in the media further exaggerated the NMDRC 
drug toxicity curves for HEK293 cells and increased cell proliferation in LLC-PK1 cell lines (Figure 
4.8). Increasing colchicine incubation time from 3 hours to 72 hours shows gradual reversion of 
the high drug dose-high cell survival curves back to the expected high drug dose-low cell survival 
relationship (Figure 4.9). To test whether this phenomenon was specific to colchicine, the same 
experiments were repeated using dexamethasone, ciprofloxacin, and rifampicin. Dexamethasone 
produced very similar NMDRC toxicity curves using HEK293 cells starting 3 hours of incubation 
time point and at 2 days using LLC-PK1 cells (Figure 4.10). Ciprofloxacin toxicity exhibited 
NMDRC drug toxicity for both cell lines in the media (Figure 4.10). Rifampicin had the expected 
conventional drug toxicity vs. drug concentration relationship for all cell types (Figure 4.10). 
Drug effects on cultured cell viability as a function of media-supplied 
growth factors 
 The presence of endogenous growth factors in cell culture media in combination with 
microtubule-destabilizing drugs were previously reported to significantly increase proximal tubule 
cell proliferation rates in initial stages of cell incubation (40). To explore whether the apparent lack 
of cell death at high colchicine concentrations resulted from this growth factor presence in cell 


































Figure 4.8. CyQuant NF® assay of immortalized cell culture viability after (A) 3 and (B) 6 hours of 
incubation with colchicine in increasing concentrations, showing NMDRC cell toxicity curves for 



















































































Figure 4.9. Time-dependent cell toxicity for HEK 293 cells from (A) 3, (B) 6, (C), 24 and (D) 72 
hours of incubation with increasing amounts of colchicine dispensed to culture with increased 























































Figure 4.10. Cell survival after incubation of the two immortalized cell lines with increasing 
concentrations of dexamethasone, ciprofloxacin, and rifampicin and increased DMSO over time: 
(A) dexamethasone after 3 hours of incubation for HEK 293 and 24 hours for LLC-PK1 cells, (B) 









Early time points – at 3 and 6 hours -- were chosen to ensure that cell death would not be 
significantly induced by lack of proteins and growth factors associated with FCS absence (see 
Supplemental Figures). Lack of media-supplied growth factors did not ameliorate or change the 
observed trend of the NMDRC drug toxicity (Figure 4.11).    
Drug effects on cell viability as a function of culture confluence  
To ascertain whether the observed NMDRC toxicity trends observed resulted from lack of 
cell-cell interactions in culture, experiments with reduced and increased DMSO in the 
drug-containing media were repeated on HEK293 and LLC-PK1 cultures using low cell seeding 
densities of 10,000 cells/well. Considering significant (almost 18-fold) reduction of cell density in 
these cultures, drug toxicity was assessed at 10-fold lower concentrations as well as 
concentrations comparable to the high-density cell cultures. All colchicine dose exposures to 
sub-confluent culture revealed cell toxicity induction at a slower rate than in high-cell density 
cultures. Even when secondary cell cultures were treated with colchicine in millimolar 
concentrations (with low DMSO additions), cell death induction required days of continuous drug 
incubation (Figure 3.12). For example, after 2 days of incubation with 2mM colchicine, both 
HEK293 and LLC-PK1 cells showed ~20% cell death as compared to untreated controls. 
Furthermore, these data in general had much more noise reflected by larger standard error bars 
(see Figure 4.12). All drug incubations produced no observed NMDRC drug dose-cell toxicity 
behavior (Figure 4.12 and 4.13). Unlike colchicine, ciprofloxacin and rifampicin produced 





























Figure 4.11. Cell toxicity due to increasing colchicine concentrations in cell culture media lacking 
FCS (no endogenous growth factors) at (A) 3 hours with HEK293 cells, and (B) 6 hours with 






















































Figure 4.12. Cell survival during incubation of increasing colchicine concentrations with 10
4
 



















































































Figure 4.13. Cell survival with increasing ciprofloxacin and rifampicin concentrations in low 
density-seeded (10
4
 cells/well) cultures. (A) and (C): ciprofloxacin at 3 and 24 hours of incubation. 












cultures. Ciprofloxacin and rifampicin exhibited pronounced NMDRC drug dose-cell toxicity 
behavior in HEK293 cell cultures at 3 hours, 24 hours, 48 hours, and 72 hours, with little 
amelioration in cell viability during prolonged incubation. Cell death appeared to be constant at 
different tested time points for ciprofloxacin, and progressive for rifampicin in this cell line. 
Amelioration of observed NMDRC drug toxicity with rifampicin in HEK293 cells was noticeable 
after prolonged drug incubation, but was not fully resolved at 72 hours. No change in NMDRC 
toxicity curves was observed with ciprofloxacin. Similar to HEK293 cells, LLC-PK1 cells exposed 
to ciprofloxacin in sub-confluent cultures showed low cell death at high drug concentrations for all  
tested time points. But unlike HEK293 cell responses, LLC-PK1 cells continued to show reduced 
cell numbers over the duration of study. Furthermore, LLC-PK1 cells cultured with rifampicin 
produced no noticeable inversion in drug toxicity kinetics at all the time points (Figure 4.13). 
Discussion 
Numerous reports on the use of immortalized kidney cells lines to measure toxicity of new 
compounds, drug delivery systems, and biomaterials continue to appear annually. Most reports do 
not explain the choice of cell models or conditions used for their toxicity or biocompatibility 
assessments, often assuming that transformed cell line monocultures in vitro on plastic respond to 
environmental stimuli similarly to their cellular counterparts in vivo. In this work we chose to test 
this assumption using two transformed kidney cell lines, HEK293 and LLC-PK1, and commonly 
employed cell culture conditions. Drug-induced cell toxicity was chosen as the simplest 




industry and academic labs, as well as due to the spectrum of cellular differentiation that these cell 
lines claim to represent. HEK293 is a human embryonic kidney cell line with non-established 
kidney cell origin (41, 42). HEK293 cells exhibit no significant brush border, contain no or low 
amounts of brush border enzymes (for example, gamma-glutamil-transpeptidase (43) and alkaline 
phosphatase (44)) or known characteristic kidney cell ligands (e.g., megalin), low endogenous 
expression of P-glycoprotein efflux pumps, and little or no expression of epithelial 
cell-characteristic transporters of charged molecules, such as OCT2 (45), organic anionic 
transporters 1-3 (OAT 1-3) (46-48), and H
+
/peptide intestinal peptide transporters 1 and 2 
(PepT1-2) (49, 50). Furthermore, HEK293 cells were found to exhibit neural cell characteristics, 
such as expression of many neuronal-specific proteins including neurofilament subunits NF-L, 
NF-M, NF-H and α-internexin (51). Overall, HEK293 can be categorized as a poorly differentiated 
kidney cell line with low endogenous expression of relevant epithelial cell markers. Dissimilar to 
HEK293, LLC-PK1 is an immortalized cell line with far greater resemblance to kidney proximal 
tubule epithelial cells. LLC-PK1 was originally derived from porcine kidney tissue (52) and found to 
retain some brush border cellular protrusions (53), cell ligands (53, 54), 
gamma-glutamil-transpeptidase and alkaline phosphatase enzymes, and a Na
+
-dependent 
transport system (11, 53, 55-57). But as for HEK293 cells, LLC-PK1 cells lack glucocorticoid 
receptors (10), and small molecule transporters (11, 12). LLC-PK1 has been shown to bear many 
similarities to in vivo proximal tubule cells regarding transcellular transport mechanisms, and is 
considered to be a model of fully differentiated adult epithelial cells (11, 53, 55, 56). In this study, 




with primary mouse kidney proximal tubule epithelial cell cultures in vitro. Cells within proximal 
tubules were isolated and cultured in a 3-D cell culture system previously shown to retain cell 
differentiation and functional potential (32). Freshly isolated proximal tubule epithelial cells are 
known to start losing their polarization as quickly as 20 min after extraction (9). Hence, a more 
complex 3-D culture was chosen to retain epithelial cell character and ensure the phenotypically 
stable primary vs. immortalized cell comparison to various nephrotoxic drug doses and times. 
HEK293 and LLC-PK1 cells were also exposed to hydrophobic drugs from different classes and 
with different pharmacological indications to assess cell toxicity as a function of cell type and not 
specific drug characteristics. Furthermore, cell titer assays with different modes of optical 
detection -- absorbance, fluorescence, and luminescence -- were selected to reduce the possibility 
of drug interference with assay read-out.  
A first important finding was recognition that assay sensitivity as well as intrinsic mechanisms 
of the assay signal production could significantly impact the data obtained. For example, the MTS 
cell titer assay, among the most abundantly used cell viability methods, was found to be relatively 
insensitive to small changes in cell numbers (Figures 3.1 and 3.2). MTS is an absorbance-based 
metabolic enzyme activity assay that estimates the number of viable cells on the assumption that 
only living cells are capable of reducing the redox-sensitive MTS dye, and that the cell treatment 
does not change the cellular metabolic rate (58, 59). MTS-obtained toxicity data did not 
discriminate cell types or drug responses with prolonged drug incubation, pointing towards intrinsic 
lack of sensitivity independent of culture conditions or drug physicochemical characteristics. 




drugs and assay reagents by measuring ATP escaping from cell cytosol during cell rupture (60, 61). 
Cell necrosis was estimated relative to the 100% cell lysis control performed as a separate 
experiment. ToxiLight® proved to be more sensitive in this respect than MTS (Figure 4.5), but was 
also found to suffer from interference with water-miscible DMSO commonly used to dissolve 
hydrophobic pharmacological agents in media (data not shown). Furthermore, because ToxiLight® 
is an ATP accumulation-based assay, upon prolonged incubation, its sensitivity drops 5-7 fold after 
3 days depending on the cell line (Figure 4.3). Overall, ToxiLight® was found to be a sensitive 
assay for time points below 24 hours of cell assessment in culture. The CyQuant NF® 
fluorescence-based assay measures cell number as a function of a DNA-binding dye (62). The 
assay was not confounded by the drugs’ intrinsic fluorescence (see Supplemental Figures).  This 
optical assay was found to be as sensitive as ToxiLight® without being affected by DMSO 
additions or cell culture conditions.  
Drug-induced toxicity in kidney proximal tubule cells in vivo is complex, involving drug 
accumulation in the cell, drug interaction with its targets, as well as possible drug 
biotransformation by cellular enzymes and metabolism by cytochrome P450 (CYPs) (27, 30, 63). 
Many influx and efflux transporters, as well as the drug’s cellular targets, are missing in 
immortalized cell lines. Hence, we sought to explore and compare cell lines’ abilities to respond to 
known drug toxicities using known pharmacological agents. Six different drugs -- neomycin, 
doxorubicin, dexamethasone, colchicine, rifampicin, and ciprofloxacin -- were selected for toxicity 
assessments in cell cultures. Neomycin and doxorubicin were purchased as soluble salt 




base or acid hydrophobic form. These differences in physicochemical properties of the tested 
agents provided additional insight into toxicity dose-response characteristics between primary and 
immortalized cells. To ensure that cell toxicity was not affected by drugs’ abilities to enter cells, all 
hydrophobic drugs employed had partition coefficient (log P) values below 2.0 (see Supplemental 
Tables, ref. (64-68)), reducing possible aggregation in full cell culture media (69). Drug-media 
aggregation potential was further reduced by using kinetic instead of thermodynamic solubility 
conditions, achieved by re-suspending drugs in DMSO prior to addition to cell culture media (70). 
Furthermore, drug aggregation was directly assessed for all drugs that showed NMDRC cell 
toxicity behavior (see Supplemental Figures). No significant aggregates above the instrument’s 
4nm sensitivity limit were observed in full media by particle size analysis, consistent with previous 
reports of low drug aggregation for molecules with logP values below 5 (69).   
Exposing HEK293 and LLC-PK1 cell lines and primary PT epithelial cells to the six drugs 
selected for this study revealed distinctive differences in cell toxicity between different formulations 
for transformed cell lines, as well as between primary vs. immortalized cell lines. Both 
immortalized cell lines produced cell toxicity proportional to drug exposure for water soluble drug 
formulations -- neomycin and doxorubicin (Figure 4.4), but exhibited non-monotonic dose 
response toxicity curves for high drug concentrations for all hydrophobic drugs but rifampicin 
(Figures 4.5, 4.6, 4.8). NMDRC drug toxicity was replicated by titer assays with different 
assessment mechanisms (Figure 4.5), and therefore is not likely to be an artifact of drug-assay 
interactions. Unlike immortalized cells, primary PT epithelial cells in a 3-D hydrogel culture (32) 




proportional to drug amounts applied to cultures, independent of drug formulation or duration of 
drug exposure (Figure 4.7). NMDRC behavior is a newly documented anomalous dose-response 
behavior observed both in vivo and in vitro (38). It is characterized by both ‘U-shape’ and ‘inverted 
U-shape’ dose-cell toxicity curves and is most commonly exhibited by endocrine-disrupting drugs 
and DNA-reactive carcinogens (71). To date over 1600 cases of chemicals responding with 
NMDRC dose-toxicity curves have been published (71). Although NMDRC and its clinical 
significance are still highly debated, several modes of NMDRC induction have been proposed: 1. a 
membrane transporter model where different subtypes of the same receptor have different 
affinities for the ligand and opposing downstream function, 2. increased DNA-repair model that is 
induced upon drug exposure, 3. increased rate of mutation model where there is cell cycle 
acceleration after toxic damage, 4. induction of proliferation model upon low drug stimulation (38). 
Current NMDRC scenarios show the breadth of possibilities that can result in atypical drug-toxicity 
relationships and these most likely do not describe all of the possible outcomes, only specific 
cases for which NMDRC behavior has been scientifically explained. From all the tested drugs in 
this study, doxorubicin was the only drug with a well-recognized DNA-damaging profile yet lacking 
NMDRC-type behavior. Furthermore, since NMDRC was prominent in these short-term culture 
experiments, proliferation and induction of mutations seems to be unlikely explanations. Hence, 
NMDRC in immortalized cell lines was mediated possibly by some form of membrane transporter 
or downstream intracellular drug detoxification mechanism. Immortalized cell lines exhibit lack of 
in vivo-relevant transporters and intracellular receptors for the tested drugs, but since NMDRC 





To evaluate whether the drugs’ intrinsic inabilities to enter cells prompted the observed 
NMDRC toxicity behavior in transformed cell lines, experiments were repeated with increased 
DMSO in the media to enhance cell permeation (39). The NMDRC cell toxicity behavior was 
retained for both HEK293 and LLC-PK1 cells (Figure 4.9, 4.10). Additionally, more pronounced 
NMDRC drug concentration-cell toxicity behavior was also observed at lower drug concentrations 
(Figure 4.9). Prolonged cell incubation with these drugs revealed that this NMDRC cell toxicity 
over time and concentration could be reversed for some drugs, like colchicine (Figure 4.9), but not 
others (i.e., ciprofloxacin, data not shown). Because both immortalized cell lines were affected and 
only LLC-PK1 cells are known to induce P-glycoprotein upon prolonged drug exposure (72), and 
at least one drug reverted to normal toxicity curves within 24 hours, it was not likely that efflux 
pumps were responsible for changing the mechanism of cell-drug toxicity profiles. The 
DMSO-enhanced drug permeability experiments were not specific enough to pinpoint membrane 
transporter mechanisms that elicit the observed NMDRC response. However, they showed that 
lack of both drug intracellular penetration and efflux were not likely reasons for atypical behavior 
observed. 
Drugs that showed NMDRC toxicity behavior in media in vitro -- colchicine, dexamethasone, 
and ciprofloxacin -- share some known capability to induce toxicity through microtubule disruption 
in mammalian cells (73-75). Previously, microtubule inhibitor drugs were shown to induce cell 
proliferation when administered with growth factors (40). Since some hydrophobic drugs induced 




growth factors (76), the hypothesis that observed lack of cell death at high drug concentrations 
might alternatively be attributed to confounding induction of cell proliferation. Drug toxicity 
experiments with colchicine, a classic microtubule-disrupting drug, in media that contained no 
growth factors were repeated at 3 and 6 hours of culture. Early time points were selected to reduce 
cell stress from depleted media-based starvation (see Supplemental Figures) and because 
previously published results ascertained early time points to be the most significant in growth 
factor-microtubule inhibitor drug synergy (40). No changes in the NMDRC drug toxicity behavior of 
colchicine were observed in the absence of serum-supplied growth factors (Figure 4.11), indicating 
that media components were not responsible for NMDRC cell toxicities. 
In vivo, paracellular transport (transport between epithelial cells) can supplement 
transcellular epithelial cell drug up-take and might be significant in vivo in kidney PT cell 
polarization-dependent toxicity mechanisms (i.e., apical vs. basal membrane drug uptake 
pathways) (26). Paracellular/transcellular comparisons for transport-aided drug accumulation and 
toxicity is irrelevant in non-confluent cell cultures lacking tight junctions. Therefore, to evaluate 
possible contributions to basal-apical receptor-facilitated drug uptake and resultant NMDRC 
toxicity, cell culture confluence effects were also explored. Methods for assessing in vitro cellular 
toxicity vary significantly in the published literature, with many methods using seeded cells 
sufficient to create a monolayer, or as few as 10,000 cells/well, which eliminates immediate 
cell-cell interactions even in a 96-well format (77-82). Data discussed to this point in this study 
used cells initially seeded/cultured at nearly 80% confluence, and producing 100% confluence for 




Figures). Experiments with low and high DMSO concentrations (i.e., less than 2% DMSO (low 
DMSO) and less than 20% (high DMSO) at highest tested concentrations) in media additions were 
repeated for colchicine, ciprofloxacin, and rifampicin with cell cultures that were seeded at 10,000 
cells/well (i.e., low density) for both LLC-PK1 and HEK293 cells. Both sub-confluent and confluent 
cultures required nearly the same drug concentration to induce toxicity. Furthermore, 
sub-confluent cultures were much slower responding to drugs with observable toxicity than 
confluent cultures for select drugs (Figure 4.12). Nonetheless, no significant changes in NMDRC 
toxicity were observed between sub-confluent and confluent cultures: drugs that exhibited 
pronounced anomalous NMDRC toxicities retained this profile, and drugs that exhibited normal 
toxicities with increasing drug concentration maintained this normal behavior in 10,000 cell/well 
cultures (Figure 4.13). These data indicate that paracellular drug uptake of hydrophobic drugs 
might be important to PT toxicity in vivo, but is not responsible for the NMDRC toxicity observed in 
the HEK293 and LLC-PK1 transformed cell lines in vitro. 
Conclusions 
This study considered several parameters commonly varied in published reports of in 
vitro-based drug toxicity assays: primary and immortalized cell lines, cell culture confluence, and 
different toxicity assessment assays. All drugs in this study have been extensively used in vivo 
with known dose-response behaviors and toxicities (83-87). Primary PT-derived cells cultured and 
tested in their native-like 3-D environment produced expected dose-response curves unperturbed 




toxicity profiles with increasing drug concentrations for three out of four tested hydrophobic drugs. 
Interestingly, all three of these drugs - colchicine, dexamethasone, and ciprofloxacin -- rely in vivo 
and in primary epithelial cultures on carrier-mediated transport (colchicine (88)), active transport 
(ciprofloxacin (89, 90)), and cellular targets (glucocorticoid receptor for dexamethasone (91)) that 
are notably absent in both LLC-PK1 and HEK293 cells (10, 92). Furthermore, rifampicin, the only 
hydrophobic drug that did not produce NMDRC toxicity in immortalized cell lines, is taken up by 
cells via passive transport pathways ubiquitous to all cells (93, 94). These data cannot distinguish 
whether observed NMDRC cell toxicity resulted from alterations to cellular drug accumulation seen 
in transformed cell lines as a result of their missing influx and efflux transporters, or due instead to 
altered ability of these secondary cells to process toxic agents due to their missing intracellular 
targets. Nonetheless, these data clearly support the need for using validated cell models that 
provide the appropriate complexity, congruence, and analogous molecular structures and 
functional pathways as primary cells as required for predicting drug interactions. Only primary 
proximal tubule epithelial cells exhibited in vivo-relevant toxicity profiles for all drugs, all 
formulations, and all time points. The LLC-PK1 immortalized cell line with many features of the 
primary proximal tubule cells showed NMDRC toxicity behavior for hydrophobic agents, but this 
atypical response was far less significant than that seen in HEK293 cells. HEK293 cells carry little 
resemblance to primary kidney cells, and exhibited atypical toxicity behavior that was not cell 
culture technique-, cell media-, or cell assay-dependent. Results from this study clearly indicate: 1) 
inability of immortalized cell lines to respond normally to toxicities imposed by many hydrophobic 




‘highly toxic’ -- for transformed cell lines experiencing the same agent under simple modifications 
to cell culture conditions, including seeding density (confluence), toxic drug exposure assay time 
point, drug log P value, or type of cell assay. 
Significant differences between primary PT and immortalized HEK293 and LLC-PK1 cell 
cultures in their ability to assess toxicity of hydrophobic agents were shown. Changes in cell 
culture methods or cell evaluation conditions produced highly variable outcomes for the same 
agents in transformed kidney cell lines versus primary proximal tubule epithelial cells.  
Immortalized kidney cell lines used for in vitro testing novel therapeutics with unknown toxicity 
modalities demonstrated little reliability to predict in vivo drug toxicity behaviors.   
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Supplemental Table 4.1. Lack of detectable drug aggregation in culture media solutions 
containing 4mM colchicine after 2 hours of incubation in different media. 















































































Supplemental Table 4.2.  General properties for drugs taken from the literature (parentheses are 
references) 























































































































Supplemental Figure 4.1. Appearance of low-confluence and high-confluence cell cultures used 
in this work showing presence or absence of cell-cell interactions important to assess drug 
influences by paracellular transport and cell polarization-dependent drug uptake. Microscopy of 
hematoxylin and eosin staining of HEK 293 and LLC-PK1 cell cultures after 5 hours of incubation 
(representative of the first 3 hour drug assessment time point, 200X): A) HEK 293 seeded at 
10,000 cells/well, B) HEK 293 seeded at 175,750 cells/well, C) LLC-PK1 seeded at 10,000 





























Supplemental Figure 4.2. Fluorescence signal standard curves for HEK 293 and LLC-PK1 
cultures as a function of cell number showing that CyQuant NF® is sensitive to distinguish optical 
signals from high cell concentrations (symbols: experimental data, lines: regression fits to data). All 





















































Supplemental Figure 4.3. Lack of detectable interference between CyQuantNF® assay signal 


































LLC-PK1, 3 hours, high DMSO
LLC-PK1, 24 hours, high DMSO
HEK 293, 3 hours, high DMSO
HEK 293, 24 hours, high DMSO
HEK 293, 3 hours, no FCS









Supplemental Figure 4.4. Control cell cultures with high DMSO content (20%) and without FCS 








COMPARING PREDICTIVE DRUG NEPHROTOXICITY BIOMARKERS IN KIDNEY 




The cellular microenvironment is recognized to play a key role in stabilizing cell differentiation 
states and phenotypes in culture. This study addresses the hypothesis that preservation of in 
vivo-like tissue architecture in vitro produces a cell culture more capable of responding to 
environmental stimuli with clinically relevant toxicity biomarkers. This was achieved using kidney 
proximal tubules in three-dimensional organoid hydrogel culture, with comparisons to conventional 
monolayer kidney cell cultures on plastic. Kidney proximal tubule cultures and two immortalized 
kidney cell line monolayer cultures exposed to known nephrotoxic drugs were evaluated for 
inflammatory cytokines, nephrotoxicity-associated genes, Kim-1 protein, cytochrome enzymes, 
and characteristic cellular enzyme shedding. Significant similarities are shown for these traditional 
biomarkers of kidney toxicity between in vivo and 3-D organoid endpoints of drug toxicity, and 
significantly, a consistent lack of clinically relevant endpoints produced by traditional 2-D kidney 
cell cultures. These findings impact both in vitro bioreactor-based kidney functional and 
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 Reprinted with permission from Biomaterials: Anna Astashkina, Brenda Mann, Glenn Prestwich, 
David Grainger. Comparing predictive drug nephrotoxicity biomarkers in kidney 3-D primary 




regenerative medicine models, as well as high-throughput cell-based drug screening validations.  
Introduction 
 Tissue-like cell interactions, cell organization, and communication in time and space in 
three-dimensions (3-D) are key in vivo variables that elicit and maintain distinct cell lineages and 
phenotypes in tissues required for tissue structure and function. Few if any of these important 
factors are incorporated into conventional cell culture monolayer systems on tissue culture plastic. 
Hence, many unanswered questions remain about the equivalence of cell monolayer cultures on 
plastic with their 3-D cultures in terms of phenotypic stability, biomarker production, or their 
respective fidelities to corresponding cells in tissues in vivo. Addressing such questions remains 
critical to asserting the validity of in vitro cell-based test systems in drug screening, toxicology, and 
models of cell signal transduction pathways required to confidently elucidate important 
physiological and pathological issues.  
A wealth of knowledge accumulated by tissue engineering and regenerative models in the last 
two decades underscores the importance of restoring or maintaining native cellular interactions 
and endogenous matrix in preserving in vivo-like cell phenotypes, behavior, and signaling; and 
tissue function and architecture (1). Specifically, matrix chemistry and mechanics, cell-cell 
paracrine signaling, and cell-matrix interactions are known to be critical for sustaining tissue-like 
activities including cell organization, proliferation, attachment, polarization, signaling, gene 
expression, morphogenesis, and homeostasis (1). New 3-D culture methods that promote, 




tissue-like architectures and functions, laying the basis for improved in vivo-relevant cell culture 
models (2, 3). Broad technical advances in tissue engineering have benefited multiple fields, 
including fundamental cell biology and physiology, organ regeneration, wound healing, drug 
development and cancer research. We describe tissue-like cultures for studying and validating 
toxicity mechanisms associated with common clinically relevant, pharmaceutically active agents.  
Drug and bioactive compound toxicity remains a major health and drug development issue:  
estimates are that only 8% of all drug candidates reach the market and almost 20% of all failures 
are attributed to some form of toxicity (4, 5). Unlike other reasons for drug candidate attrition in 
clinical trials, toxicity failure rates have not changed in the last two decades, reflecting a poor 
understanding of in vivo drug-host interactions and lack of appropriate cellular models (5). 
Nephrotoxicity, or kidney toxicity, is the second-leading cause of drug-induced damage after 
hepatotoxicity in critically ill patients and is thought to cause as many as 25% of all kidney failures 
in this group (6). Nephrotoxicity describes a complex process of tissue damage due to active and 
passive agent accumulation in the kidneys and their chemical alterations through interactions with 
cellular enzymes, particularly cytochrome (CYP) P450 enzymes (7). The compound nature of 
kidney cellular injury in vivo requires that simpler cell-based models intended to recapitulate its 
mechanisms with any fidelity should retain cellular structures involved in toxicity induction. 
Specifically, preservation of brush border and intracellular enzymes γ-glutamyl-transferase and 
glutathione known to process chemotherapeutic platinum drugs (8); ligands involved in 
endocytosis of small molecules such as megalin-induced endocytosis of aminoglycosides (9); 




accumulation using organic cationic transporter 2 (OCT 2) (7); and stable cytP450 expression 
capable of drug biotransformation to metabolites (8) are minimal competences for such models in 
drug toxicity testing. We have previously shown that 3-D proximal tubule (PT) organoid cultures in 
hyaluronic acid (HA) hydrogels retain all of these in vivo-toxicity relevant cellular bioactivities 
through maintenance of 3-D cell architecture and cell-cell interactions. This work probes the 
relationships between 3-D cellular organization and production of clinically relevant cellular 
biomarkers of toxicity in vitro, as well as comparison of the 3-D organoid cultures to the cell culture 
“gold standard”: 2-D cultured monolayers of kidney secondary cells on rigid tissue culture 
thermoplastic.  
Methods 
Drugs and bioactive agents  
All bioactive agents were purchased from Sigma-Aldrich (USA). Doxorubicin (doxorubicin 
hydrocholoride), colchicine, cisplatin (cis-diaminedichloro-platinum II) and PAP were dissolved in 
dimethyl sulfoxide (DMSO, Fisher Scientific, USA) to stock solutions and stored at -20°C. 
Doxorubicin was resuspended at 1 mM concentration and all other molecules were used from 
20mM stock solutions. Prior to cell application, all drugs were diluted to their final concentrations in 
proximal tubule media (1% fetal calf serum, 5% sodium pyruvate, 1% non-essential amino acids, 
1% insulin/transferrin/selenium,1% antibiotic-antimycotic, 0.9 µg of hydrocortisone, phenol 
red-free Dulbecco's modified Eagle medium (DMEM)-Ham's F-12 with L-glutamine and 




pore-sized sterile filter (ISC Bioexpress, USA). Phenol red-free media was used in order to avoid 
color interference with luminescence and fluorescence cell viability measurements. All reagents 
for cell culture were purchased from Invitrogen (USA). 
Culture plate preparation for PT 3-D organoid constructs 
Non-tissue culture polystyrene plates (96-well, ISC Bioexpress) were coated with transparent, 
non-toxic Teflon-AF® (Dupont, USA) thin films in FC-40 (3M, USA) solvent per published protocols 
(10). Solvent was removed using heated vacuum drying and plates sterilized using UV irradiation 
for 30 min before use. 
PT isolation and 3-D hydrogel construct fabrication  
Male C57BL/6 mice 6-8 weeks old were purchased from Jackson Laboratories (Bar Harbor, 
USA). PTs were isolated according to published methods (11). Briefly, animals were euthanized 
using carbon dioxide according to approved University of Utah IACUC protocols. All procedures 
used standard aseptic conditions in a BSL2 laminar flow hood. Freshly harvested kidneys were 
isolated by removal of the kidney capsule, blood vessels, and ureter. Cleaned kidneys were finely 
mechanically disrupted and enzymatically digested in collagenase IV (Worthington Biochemical 
Corporation, USA), DNAse I (Sigma Aldrich, USA), and hyaluronidase (HAse, Worthington 
Biochemical Corporation) enzyme KREBS solution (145 mM NaCl, 10 mM HEPES, 5 mM KCl, 1 
mM NaH2PO4, 2.5 mM CaCl2, 1.8 mM MgSO4, 5 mM glucose, pH 7.3) at 37
ᵒ
C (12). Digested 
sections of the nephron were then enriched for PTs using serial 80 µm and 250 µm sized sieves 




biomedical grade carboxymethylated HA (CMHA-S, SentrX Animal Care, Salt Lake City, USA) in 
PBS
++
, and crosslinked chemically and directly in situ by addition of 7.5% poly(ethylene glycol) 
diacrylate (PEGDA, SentrX Animal Care, Salt Lake City, USA) bifunctional electrophile (4:1 v/v 
CMHA-S:PEGDA, total volume 50µL) into the 3-D constructs (2, 3). Crosslinking was performed for 
35 min in 96-well TeflonAF®-coated culture plates in an incubator followed by PT media addition, 
producing soft hydrogels under conditions that do not affect cell viability or function (2). Culture 
constructs comprised approximately 5000 PTs/well and were used within 2 weeks of preparation. 
The 3-D constructs were maintained in a cell culture incubator under 5% CO2 and 95% air and 
culture media were exchanged every other day for optimum PT viability.  
Immortalized kidney cell line monolayer cultures  
Immortalized transformed porcine LLC-PK1 renal PT epithelial cells were purchased from 
ATCC, USA. Immortalized transformed human embryonic kidney (HEK 293) renal proximal tubule 
epithelial cells were generously donated by Dr. Alfred Cheung (University of Utah, USA). Cell lines 
were expanded using aseptic techniques in DMEM with 10% fetal bovine serum (FBS) and 1% 
antibiotic-antimycotic. Both cell lines were maintained in cell culture incubators under 5% CO2 and 
95% air at 37°C. 
All studies but the cytochrome 2-D culture monolayer experiments used cells seeded in 
96-well tissue culture plates (Fisher Scientific, USA) at 170,750 cells/well density, approximately 
equivalent to 5000 PTs/well. Cells were adhered for 2 hours in DMEM with 10% FBS and 1% 




cells cultured as 2-D monolayer and 3-D organoid culture used 96-well tissue culture treated 
imaging plates (BD Falcon, USA). Immortalized cells were seeded at 170,750 cells/well and 
allowed to adhere overnight prior to drug exposure on imaging plates for the cytochrome induction 
due to inferior cell adhesion compared to regular tissue culture polystyrene substrates. 
EC50 determinations 
The EC50 values for 3-D and 2-D cultures exposed to nephrotoxic drugs were determined 
after 3 days of incubation with each drug. This time point was chosen to provide cells both grown 
as monolayers and suspended in HA gels sufficient time for uniform drug diffusion and exposure. 
Drug diffusion in the HA gel was first tested using cisplatin as a model since all drugs had 
comparable molecular weights, but basic, amine-bearing cisplatin had the greatest electrostatic 
interaction with the HA gels. Cisplatin was resuspended in water and placed on an HA gel surface 
without cells, cast over transwell microporous inserts (Corning, USA). Transwell® inserts with 
diameters compatible with 96-well plates were placed in a 24-well plate (Flow Laboratories, USA) 
with 500µL of water/well. The entire volume of the well was removed at 1-24 hour time points and 
appearance of cisplatin below the Transwell® filter was assayed spectrophotometrically (Synergy 
2) at A260 and A280. 
The commercial CyQuant NF® (Invitrogen, USA) assay was used to measure cell numbers 
for 2-D and 3-D cultures through nucleic acid labeling. For 2-D experiments, cell concentration 
was assessed using the standard manufacturer’s protocol. For 3-D experiments, HA gel 




the gel for 1 hour in the incubator. CyQuant NF® solution was prepared according to 
manufacturer’s instructions and applied directly to the constructs. Supernatant was analyzed using 
a fluorescence microplate reader (Synergy 2, USA). CyQuant NF® measurements for blank HA 
gel without cells were subtracted from 3-D organoid constructs as a background. Amount of drug 
trapped by the HA gel was estimated using depletion methods for all tested drugs. Specifically, 
gels without cells were incubated with EC50 drug concentrations in water for 3 days in the 
incubator. Amounts of drug both prior to and post gel incubation in the medium were measured 
using a Cary 400 Bio UV-VIS spectrophotometer (Varian, USA) and a Nanodrop instrument 
(Thermosciences, USA). Drug presence was evaluated at A290 for cisplatin, A340 for colchicine, A219 
for PAP, and A489 for doxorubicin. Solutions removed from the gel were adjusted for evaporation in 
final concentration determinations. 
Shedding of cellular enzymes 
 NAG and γ-glutamyl-transferase shedding into urine are clinical indications of drug-induced 
nephrotoxicity (13, 14). Enzyme concentrations in the media from 2-D primary cells and 3-D 
organoid cultures were assessed after 3 days of drug incubation at corresponding EC50 values. 
Optical absorbance of drugs in the media was subtracted as background.  
NAG is an intracellular enzyme measured in the media according to published chromogenic 
protocols (13, 14). Briefly, 100 µL of the media was incubated for 10 min at room temperature (RT) 
with 100 µL of 2.24mM p-nitrophenyl-N-acetyl-β-D-glucosaminide (Sigma Aldrich, USA) dissolved 




405 nm on the microplate reader and referenced against a 1 mM 4-nitrophenol standard (Sigma 
Aldrich, USA). Negative values for NAG concentration were shown as zeros. 
 Gamma-glutamyl-transferase is a brush border enzyme assessed according to a standard 
chromogenic protocol (15). Briefly, 50µL of media from each construct was pre-incubated with 50µL 
of assay solution (150mM NaCl and 10mM Tris-HCL, pH 8.5) for 5 min at RT. The reaction was 
initiated by adding 50µL of 5mM L-glutamyl-p-nitroaniline (Sigma Aldrich, USA) chromogenic 
substrate with 100mM glycylglycine (Sigma Aldrich, USA). The reaction was allowed to proceed for 
20 min in the incubator and stopped using 200µL of 10% acetic acid. Amount of the chromogenic 
product was assessed using a spectrophotometer at A405 and referenced against a 1 mM reading of 
p-nitroanilide (Sigma Aldrich, USA). 
Staining for cellular cytP450 ,TNF-α, and Kim-1 markers  
Changes in of cytP450 enzyme expression is an indicator cell toxicity (16). LLC-PK1, HEK 293, 
and 3-D PT organoid cultures were assessed for expression of common mouse cytP450 enzymes, 
CYP2B2 and CYP2E2, after 3-day exposure to active molecules at their corresponding EC50 values 
using immunofluorescence. Both anti-mouse CYP2E2 and CYP2B1/2 antibodies were purchased 
from Millipore (USA).  
TNFα and Kim-1 protein up-regulation on cell surface is another specific signature of 
nephrotoxicity (17, 18). TNFα and Kim-1 were analyzed on LLC-PK1, HEK 293, and 3D PT 
organoid cultures after 3 days of drug exposure at their corresponding EC50 values (see Table 5.1). 




Table 5.1.  Effective EC50 values for nephrotoxic drugs in different kidney cell line (2-D 
HEK293, LLC-PK1 monolayers) and primary PT 3-D hydrogel cell cultures. Data reflect 
background subtraction of drug adsorption to HA gel matrix (see Materials and Methods). 
 
Drug 2-D HEK293 2-D LLC-PK1 3-D PTs 
Cisplatin 2.7mM 2.0mM 0.42mM 
Doxorubicin 2.3µM 1.9µM 1.4µM 
Colchicine 4mM 2.1mM 24.4µM 



















was generously donated by Dr. Joseph V. Bonventre (Harvard University, USA). Both cells 
cultured in 2-D monolayers on plastic and in 3-D scaffolds as hydrogels were fixed using 4% 
paraformaldehyde. Monolayer cell culture was fixed for 30 min at RT and 3-D organoid PT 
constructs were fixed overnight in a 4
ᵒ
C refrigerator. Both 2-D and 3-D cell cultures were 
pretreated with 0.1% Triton X in the case of cytP450 CYPs and KIM-1, but not TNF-α, and blocked 
using Invitrogen’s signal enhancer at RT for 30 min and 1 hour, respectively. Primary antibody was 
then applied for 2 hours at RT into cell monolayers and 3 days at 4
ᵒ
C on 3-D organoid cultures. 
Alexa-488 goat-anti-mouse IgG antibody (Invitrogen, USA) was used as a secondary antibody for 
all CYP proteins. Cells stained for Kim-1 and TNF-α were stained with secondary Alexa-488 
anti-rabbit IgG. All primary antibodies were used at 1:1000 dilutions except for Kim-1 used at 1:500; 
secondary antibodies were used at 1:1000 concentrations. All cells were imaged at 400X 
magnification on an Olympus FV1000 Spectral confocal microscope. Each sample was evaluated 
as an average of 3 images for secondary cells and 4 images for primary cells. ImageJ free 
software was used to analyze fluorescence intensity and number of nuclei per sample.  
Quantitative polymerase chain reaction (qPCR)  
Several genes were identified in vivo as sensitive, specific biomarkers of kidney toxicity 
(19-23). Immortalized cell lines and primary 3-D PT organoid cultures were tested for induction of 
neutrophil gelatinase-associated lipocalin (NGAL), osteopontin (Spp1), clusterin (CLU), vimentin 
(VIM), heme oxygenase-1 (HO-1) at corresponding EC50 values after 3 days of incubation with 




USA) protocol. Final mRNA samples were treated with DNAse I (Sigma-Aldrich) to eliminate 
genomic DNA contamination. RNA samples were diluted in nuclease-free water (Invitrogen, USA) 
to 300 ng/µL for primary cells and 100 ng/µL for immortalized cell lines. qPCR was performed using 
commercial TaqMan® Gene expression Assays (Applied Biosystems, USA): Mm9999915_g1 for 
GAPDH, Mm01324470_m1 for Lcn2 (NGAL), Mm004427773_m1 for CLU, Mm00516005_m1 for 
HO, Mm01333430_m1 for VIM, Mm00436767_m1 for Spp1. GAPDH was chosen as a 
housekeeping control due to low variation between drug-treated and control samples. Gene 
amplification was performed using RNA-CT Taqman Kit (Applied Biosystems, USA) on Step One 
Plus qPCR cycler (Applied Biosystems, USA). QPCR data were analyzed using the 2
-ΔΔC
T method 
(24). Samples that did not express genes after 40 cycles were assigned 41-cycle expression for 
calculations.     
Statistics  
All data analysis used Excel 2010 (Microsoft) and GraphPad Prism 5 (GraphPad Software, 
Inc.). All cell experiments were performed using three to six independent samples with two 
technical replicas. For the 3-D PT organoid cultures, independent samples used cells isolated from 
different mice. Data were evaluated using unpaired student’s test with Hochberg’s post-hoc 
procedure to adjust for multiple comparisons. Observations were considered to be statistically 







EC50 values in primary 3-D and cell line 2-D cultures 
Apoptosis in in vitro cultures is a common measurement after toxic agent exposure. Although 
reduction of cell numbers has no corresponding values in vivo, it can be used for comparative 
purposes of relative toxicity between different compounds in vitro. EC50 values were defined as the 
amounts of drug required to kill 50% of cells after 3-day incubations (see Supplemental Figures). 
HA gels were found to significantly interact with all drugs tested except doxorubicin; specifically, 
drug binding in the gel was measured to be 74% for cisplatin, 39% for colchicine, and 50% for PAP. 
The 3-day time point of drug exposure was selected to reduce diffusion differences between 2-D 
and 3-D cell culture, since drug diffusion experiments through the HA gel showed that drugs may 
take 1-4 hours to penetrate through these gels (data not shown). Quantification of cell apoptosis in 
cultures revealed 1.6-164-fold differences in EC50 values between 3-D primary and cell line 
monolayer cultures, with primary 3-D organoid cultures exhibiting greater sensitivity to drug 
exposure (Table 5.1). Colchicine exhibited the greatest difference and cisplatin the least difference 
in toxicities between two cell culture conditions.   
NAG and γ-glutamyl-transferase release into culture media  
Shedding of intracellular and extracellular enzymes is a signature of proximal tubule cell 
damage and is commonly assessed in an in vivo setting (13, 14). NAG is a lysozomal enzyme and 




both NAG and γ-glutamyl-transferase in the media were determined after 3 days of incubation with 
drugs at drugs’ corresponding EC50 values using colorimetric assays. Both HEK 293 and LLC-PK1 
cell lines grown on 2-D plastic responded to toxic agents without a specific pattern (Figure 5.1). 
PAP and cisplatin did not elevate γ-glutamyl-transferase in a statistically significant way and all 
tested drugs had no effect on NAG production (Figure 5.1). Conversely, colchicine increased 
γ-glutamyl-transferase in HEK 293, while doxorubicin and colchicine elevated the same protein in 
LLC-PK1 (Figure 5.1). Organoid 3-D cell culture of PTs responded to nephrotoxic drug exposure 
by up-regulating both NAG and γ-glutamyl-transferase for all drug molecules (Figure 5.1). 
Increase in NAG was more consistent between the various drugs assayed in 3-D cultures, 
possibly reflecting greater responsiveness of the 3-D organoid culture to produce this protein in 
response to drug toxicity as in vivo. 
Expression of TNF-α  
Inflammation and tissue damage are two processes common in drug toxicity (18, 25). TNFα 
was previously found to be up-regulated by proximal tubule cells in response to nephrotoxic drugs 
in vivo (18, 25). Cytokine production was tested at corresponding EC50 for different drugs after 3 
day exposure. Surface-bound TNFα was up-regulated for PAP, doxorubicin, and cisplatin, but not 
for colchicine in the 3-D organoid culture and for doxorubicin and colchicine in LLC-PK1 cells (see 
Figure 5.2, Supplemental Figures). HEK 293 produced large changes in TNFα that were not 














































































Figure 5.1. γ-glutamyl-transferase (GT) and NAG release into media at drugs’ EC50 values in 
different kidney cell cultures (PT = 3-D hydrogel; LLC-PK1 and HEK293 are 2-D monolayers on 












































Figure 5.2. TNF-α expression on cultured cell surfaces at drugs’ EC50 values in different kidney 
cell cultures normalized to control (PT = 3-D hydrogel; LLC-PK1 and HEK293 are 2-D monolayers 



















Expression of CYP450 enzymes  
Proximal tubule epithelial cells are metabolically active cells, with both CYP2E1 and CYP2B1 
abundantly present in mouse kidney PTs (26). Furthermore, these two cytochromes are regulated 
by many endogenous agents (16). Changes in CYP2E1 and CYP2B1 levels were measured after 
3 days culture at all drugs’ corresponding EC50 values. CYP2B1 was up-regulated exposed to 
doxorubicin and colchicine in LLC-PK1; and with colchicine in HEK 293 cells (Figure 5.3). Very 
little expression of CYP2B1 was found in HEK 293 compared to LLC-PK1 immortalized cells (see 
Supplemental Figures). CYP2E1 was induced by cisplatin in PTs; doxorubicin in LLC-PK1; and 
colchicine in HEK 293 cells (Figure 5.4). Similar expression of CYP2E1 was detected in both 
transformed cell lines (see Supplemental Figures). 
Induction of Kim-1  
Kim-1 up-regulation is associated with the kidney proximal tubule tissue damage in vivo (17, 
27). Kim-1 protein assay used immunohistochemistry in 3-D organoid culture and LLC-PK1 and 
HEK 293 immortalized cells. No staining was achieved in transformed cell lines (data not shown). 
All drugs produced some up-regulation of Kim-1 in primary cells (Figure 5.5), with greatest staining 
in cisplatin and doxorubicin-treated cells. All Kim-1 drug-induced staining seemed to be cytosolic 

















































Figure 5.3. CYP2B1 intracellular expression at drugs’ EC50 values in different kidney cell lines 
normalized to control (PT = 3-D hydrogel; LLC-PK1 and HEK293 are 2-D monolayers on plastic; 





















































Figure 5.4. CYP2E1 intracellular expression at drugs’ EC50 values in different kidney cell cultures 
normalized to control (PT = 3-D hydrogel; LLC-PK1 and HEK293 are 2-D monolayers on plastic; 














Figure 5.5. Fluorescence microscopy of immuno-stained Kim-1 intracellular expression at drugs’ 
EC50 values in 3-D PT cultures. A) PTs not treated with drugs (control), B-E) PTs treated with: B) 


















































































Stimulation of nephrotoxic biomarker genes  
Several genes are up-regulated with proximal tubule cell damage in vivo. Gene up-regulation 
in primary 3-D culture of PTs and monolayer cell lines was analyzed using qPCR. No 
up-regulation above 2-fold expression changes was observed in HEK 293 cells except for VIM in 
case of doxorubicin treatment (Figure 5.6). LLCP-K1 cell treated with drugs induced VIM for all 
drugs except PAP; NGAL and HO for PAP and cisplatin; and Spp1 for cisplatin (Figure 5.6). 
Primary 3-D organoid culture of PTs up-regulated all tested genes for all drugs (Figure 5.6). Lack 
of statistical significance for immortalized and primary cells was primarily attributed to large 
variations between samples. 
Discussion 
Immortalized cell lines are commonly used for nephrotoxicity assessment due to the fact that 
primary epithelial kidney cells start to lose their cellular characteristics within 20 min. after isolation 
and completely de-differentiate within weeks in 2-D culture (11, 28). Unfortunately, immortalized 
cell lines have limited resemblance to their primary analogs and commonly lack essential 
molecular structures critical for toxicity induction with any clinical relevance (9, 28, 29). For 
example, the two transformed cell lines used on this study, HEK 293 and LLC-PK1, are reported to 
be missing small molecule transporters responsible for drug uptake, including organic cationic 
transporters 1-3 (OAT 1-3), OCT 2, and H
+
/peptide intestinal peptide transporters 1 and 2 (PepT 
1-2), intracellular drug targets, such as glucocorticoid receptors, and low levels of drug efflux 






















































































































































































Figure 5.6. Distinctly different nephrotoxic gene expression profiles at drugs’ EC50 values in 
different kidney cell cultures (n=3-6, mean±SE): A) NGAL, B) VIM, C) CLU, D) HO, and E) Spp1. 





(30), cellular extensions that promote molecule and water re-absorption, (ii) an absence of cellular 
ligands such as megalin, which are critical for albumin and aminoglycoside endocytosis (31), and 
(iii) minimal alkaline phosphatase activity, an apical enzyme essential for cell signaling induction 
(32). Lack of these (and possibly other) cellular components makes immortalized kidney cells poor 
models for toxicity assessment of novel drug compounds, drug delivery vehicles, and biomaterials  
with unknown modes of toxicity induction. Furthermore, absence of cellular complexity limits the 
type of toxicity biomarkers that might be correlated or discovered from transformed cell lines for 
drug development or clinical translation. Most in vitro studies report decreased cell viability or 
proliferation as endpoints for toxicity assays, data not easily translated to equivalent values in vivo. 
Ideally, in vitro cultures would respond to toxic agents by expressing clinically relevant biomarkers 
that facilitate direct comparisons between in vitro and in vivo results. 
In this study, an organoid 3-D culture of kidney PT epithelial cells previously shown to retain 
primary cell differentiation status and functionality for weeks in vitro in culture was assessed for in 
vivo-relevant toxicity biomarkers after exposure to known nephrotoxic drugs. A well-published and 
extensively used, commercialized hyaluronic acid-based hydrogel biomaterial was used to 
encapsulate PT isolates exploiting mild Michael addition reactions (2,3). The advantages of this 
gel system are that HA gels: 1. do not contain proximal tubule cell adhesive sites, inhibiting PT 
cells from out-migrating from PTs and importantly, compelling them to remain associated within 
PTs during prolonged in vitro culture, 2. contain no catalyst/additives that affect cell viability, 3. 
quickly gel in situ around living cell or tissue isolates in the incubator or at room temperature, and 4. 




primary and immortalized cell phenotypes.   
A series of clinically used drugs -- cisplatin, doxorubicin, PAP, and colchicine -- with known and 
varying nephrotoxicity in vivo were chosen for evaluation. Cisplatin is a potent, platinum-based 
drug that kills cancer cells through crosslinking DNA, and a common chemotherapeutic agent 
used to treat several forms for cancers, including carcinomas, sarcomas, and lymphomas (7). 
Cisplatin’s clinical use is primarily limited by its nephrotoxicity, affecting as many as 14-100% of all 
patients receiving the therapy (33). Beyond apoptosis induced through its DNA binding, cisplatin in 
PT epithelial cells can be transformed through interaction with brush border enzymes and CYP 
enzymes (34). Doxorubicin is another chemotherapeutic agent commonly clinically used to treat 
soft tissue sarcomas, carcinomas, and hematological malignancies, affecting proliferating cells 
(e.g., cancer cells) through DNA intercalation and interaction with topoisomerase II enzyme, 
effectively inhibiting DNA replication. Doxorubicin exhibits multiple-organ adverse effects, including 
nephrotoxicity. The exact mechanism of doxorubicin-induced nephrotoxicity is unknown, but is 
suggested to involve oxidative stress, lipid peroxidation, and protein oxidation as contributors to 
kidney pathology associated with this drug (35). PAP is paracetimol’s (e.g., acetominophen) 
metabolite found to induce PT-specific toxicity (36). Similar to cisplatin, PAP is thought to exert 
toxicity though biotransformation via γ-glutamyl-transferase and targeting of mitochondria (36). 
Colchicine is an anti-inflammatory drug approved to treat gout and familial Mediterranean fever. As 
a classical microtubule inhibitor drug, colchicine induces apoptosis in rapidly dividing cell by 
microtubule polymerization and mitosis inhibition (37). Colchicine’s therapeutic use for other 




Colchicine is a suspected proximal tubule-disrupting drug, since microtubule disruption was 
previously linked to disruption of endocytosis, membrane recycling, and polarized distribution of 
aquaporin-1 and gp330. Given these drugs, cisplatin would be considered the most potent 
proximal tubule nephrotoxicant, followed by doxorubicin and PAP, while colchicine can be 
classified as an alleged kidney toxicity agent.    
Toxicity biomarkers for these studies focused on assays commonly performed for in vivo drug 
studies rather than in vitro assays. This design was proposed to distinguish current approaches in 
2-D cell-based in vitro toxicology testing and performance distinctions for new 3-D organoid 
culture methods, both relative to documented in vivo toxicities for each drug. As a first step, EC50 
values for drugs in confluent monolayer cell cultures of HEK 293, LLC-PK1, and primary PT 
epithelial cell in 3-D hydrogel cultures were established (Table 5.1). Data in Table 5.1 serve two 
main purposes: 1) to compare a common toxicity indicator currently used in the literature, and 2) to 
establish a reference point for these cell models for further experiments. Significant differences in 
cell viability were found between immortalized kidney cell lines grown in 2-D versus those in 
primary organoid 3-D models. Primary cells proved to be 1.6-164-fold more sensitive to drugs 
compared to transformed cell lines (Table 5.1). Colchicine produced the greatest EC50 difference 
and doxorubicin exhibited the least significant alteration in cell viability. Because all tested agents 
belonged to distinct drug families, it is difficult to speculate on the nature of such significant 
variations in drug EC50 values between cell models, but it is worth noting that colchicine produced 
the greatest differences among the immortalized cell lines. HEK 293, the transformed cell line 




drugs. Hence, lack of drug-induced cell death could be due to the oversimplified nature of the 
kidney cell lines. 
Kidney toxicity is a common side effect of clinical pharmacology interventions for numerous 
pathologies. Several biomarkers have been explored with varying degrees of sensitivity, epithelial 
cell specificity, and expediency of up-regulation in response to drug-induced injury. Several of 
these in-vivo-relevant biomarkers were selected for monitoring in the 3-D organoid PT cell culture. 
Specifically, this included the induction of soluble proteins linked to kidney injury including NAG, 
γ-glutamyl-transferase, and Kim-1; TNFα cytokine up-regulation in inflammation concomitant to 
epithelial damage; down-regulation of drug-specific cytochrome P450 enzymes; and stimulation of 
nephrotoxicity-associated genes.  
NAG and γ-glutamyl-transferase 
Epithelial cell damage in vivo is commonly correlated to increases in NAG and 
γ-glutamyl-transferase in the urine of patients or animals (13-15). NAG is a high molecular weight 
lysosomal enzyme highly active in kidney PT cells (38). NAG appearance in tubular fluid is 
commonly associated with PT necrosis in vivo due to a variety of kidney diseases and 
inflammatory processes (38). Although NAG measurement in urine is still not a part of a standard 
hospital kidney damage panel, many clinical studies have shown that its changes are a useful 
indicator of ongoing tubular injury (38). Gamma-glutamyl-transferase is another active PT enzyme 
Located on the brush border of the PT cells, γ-glutamyl-transferase  is an important part of the 




detoxification pathway for reactive species (39). Elevation of γ-glutamyl-transferase levels is a 
known indicator of cell damage and is currently a standard assay of liver problems. The increase 
of γ-glutamyl-transferase maybe a useful marker of PT damage by barbiturates, 
chemotherapeutics, aminoglycoside antibiotics, nonsteroidal anti-inflammatory drugs, chronic 
kidney damage and inflammation (26). Drug exposures to all cell lines at their EC50 values 
produced measurable amounts of NAG and γ-glutamyl-transferase but there were noteworthy 
differences in their up-regulation among the cell models. Specifically, similar to in vivo data, 3-D 
organoid culture had significant induction of NAG and γ-glutamyl-transferase enzymes in the 
media for all drugs tested (Figure 5.1). In primary cells, NAG stimulation exhibited less variation 
between experiments and appeared more sensitive as a toxicity marker than 
γ-glutamyl-transferase. Overall, no NAG up-regulation was associated with cell damage and only 
a few less toxic drugs produced γ-glutamyl-transferase induction in the immortalized cells. In 
contrast, primary cells responded to drug-induced cell damage with in vivo-relevant trends (14, 
15).  
Inflammatory protein production 
Previous studies indicate that PT epithelium may be involved pro-inflammatory events linked 
to drug-induced toxicity, leading to the acute kidney injury (AKI) (18, 25). Initial injury is thought to 
initiate a sequence of events resulting in cell phenotypic changes and cytokine/chemokine 
induction that attracts immune system cells to the injury site. In the drug-induced AKI model, 




production of monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein 1α 
(MIP-1α), and regulated upon activation normal T-cell expressed and secreted (RANTES) 
chemokines, contributing to tissue injury and inflammatory kidney disease (25). Additionally, TNFα 
is central to kidney structural damage and renal dysfunction in cisplatin-induced AKI (18). 
Inhibition of TNFα production in vivo resulted in down-regulation of transforming growth factor β 
(TGF-β), RANTES, MIP-2, MCP-1, and interleukin 1β (IL-1β) cytokines, while TNFα-deficient mice 
were resistant to drug’s nephrotoxicity, suggesting the cytokine’s key relevance to 
cisplatin-induced pathogenesis (18). The PT 3-D organoid culture demonstrated significant 
up-regulation of TNFα in cells treated with cisplatin, PAP, and doxorubicin, similar to that reported 
for these drugs in vivo (Figure 5.2) (18, 40, 41). Furthermore, the 3-D PT culture lacked statistically 
significant TNFα induction upon exposure to colchicine, similar to reports in animal studies, 
reflecting colchicine’s ability to decrease TNFα protein expression on cell surfaces as a result of 
impaired cytoskeletal organization (Figure 5.2). Unlike primary cells, immortalized cells showed no 
statistically significant changes or sporadic up-regulation in TNFα (see Figure 5.2, Supplemental 
Figures). These data point to significant similarities in pro-inflammatory cytokine production 
between in vivo and 3-D organoid cultures, and limited expression of inflammatory mediators 
produced by traditional 2-D kidney cell line cultures. 
CYP enzymatic response 
The PT epithelium consists of metabolically active cells. Central to this function, the 




xenobiotic environmental agents (42). CYP2B1/2 and CYP2E1 are some of the most common, 
highly produced P450 isoforms that are crucial for biotransformation of toxic compounds in 
rodents (16). Furthermore, given the significant distribution of kidney-active CYPs in different 
species, both CYP2B1 and CYP2E1 have been previously shown in porcine LLC-PK1 cells as 
capable of processing chemotherapeutic drugs cisplatin and ifosfamide (43). Humans are not 
known to express either enzyme in the healthy kidney tissue, but there is no information about their 
possible up-regulation in response to toxicants (16). CYP2B1 and CYP2E1 induction was 
measured in all three cell cultures assayed here, with both enzymes producing staining in all 
samples measured (see Figures 5.3, 5.4 and Supplemental Figures). CYP2B1 expression in HEK 
293 cells was very low, almost 8-fold less than in LLC-PK1 cells (see Supplemental Figures). 
CYP2E1 expression was similar between the two immortalized cell lines (see Supplemental 
Figures). In vivo, kidney exposure to cisplatin down-regulates CYP2E1 content in the PT 
epithelium, generating reactive oxygen species, hydrogen peroxide, and catalytic iron, resulting in 
cisplatin-induced apoptosis. Doxorubicin, colchicine, and PAP are not known to be substrates for 
either CYP2B1 or CYP2E1. Comparing in vitro to current in vivo data on drug cytochrome 
induction, it is clear that the immortalized cells produced no information consistent with clinical 
data. On the other hand, 3-D organoid culture correctly predicted cisplatin down-regulation of 
CYP2E1. Stimulation of cytochrome P450 enzymes in drug-induced models suggests that 3-D PT 
organoid culture has greater predictive potential for in vivo drug-CYP interactions than 
immortalized cell lines, which not only poorly reflect animal data but have produced many 





Nephrotoxicity biomarkers commonly lack sensitivity in predicting early events associated 
with kidney injury. Kim-1 (also called Tim-1) is a type I cell membrane glycoprotein with mucin-like 
and immunoglobulin-like extracellular domains that induce phagocytic properties in PT epithelial 
cells. Kim-1 specifically recognizes molecular apoptosis epitope, phosphatidylserine, and oxidized 
lipoproteins on the surfaces of damaged epithelial cells, and directs them to lysosomes for 
degradation (17, 27). Up-regulation of Kim-1 in PTs leads to removal of apoptotic cells in a timely  
fashion, presumably avoiding secondary necrosis and aiding in tissue remodeling and restoration 
of PT function (17). Kim-1 is shown to significantly up-regulate in response to drug-, ischemia-, 
and environmental agent-specific injury in a dose-responsive manner (17, 27, 44). It has been 
shown to outperform other biomarkers of kidney damage in humans, and is even thought to be 
predictive of post-surgical complications within hours of the medical procedure. Given the central 
role of Kim-1 in kidney damage, its endogenous production was evaluated in secondary cell lines 
and 3-D primary cells. The three-day time point was chosen due to original discovery of elevated 
Kim-1 mRNA induction during the first 48 hours after the initial injury (44). No protein staining by 
murine Kim-1 antibody in the immortalized cells was observed (data not shown). This was 
attributed most likely to lack of protein production in these cells since HEK 293 had poor 
endogenous production of kidney proteins and LLC-PK1 cells have been used as an expression 
cell line for Kim-1 expression constructs (27). Unlike immortalized cells, 3-D PT organoid cultures 
showed induction of Kim-1 in response to all drugs (Figure 5.5). Cisplatin and doxorubicin seemed 




distribution. Specifically, cisplatin produced more diffuse cytoplasmic distribution as previously 
observed in vivo (45), but doxorubicin had more nucleus-associated Kim-1 localization. Since only 
one time point was observed, variances in cellular localization could be due to differences in 
protein induction kinetics by the different drugs (cytoplasmic for cisplatin, PAP, and colchicine and 
punctate for doxorubicin). Data on Kim-1 up-regulation, similar to other information collected in this 
study, point to dissimilarities between differentially stable primary cells and immortalized cell lines 
in production of clinically important biomarkers of toxicity in response to environmental assaults. 
Induction of nephrotoxicity-associated genes  
Several gene products have been identified as predictive of early PT epithelial drug-induced 
damage. In this work, several of the most prominent biomarkers -- NGAL, VIM, CLU, HO-1, Spp1 
-- were tested in immortalized and primary tissue replacement 3-D culture upon exposure to 
nephrotoxic drugs. NGAL is a cytosolic (or secreted) protein that belongs to the lipocalin 
superfamily (20). NGAL was first discovered in activated neutrophils, but was subsequently found 
to be inducible by many different cells in response to injury. NGAL in PT epithelial cells was shown 
to be induced in vivo in response to AKI and chronic kidney disease (CKD), but most researchers 
found NGAL protein to be elevated within hours of acute kidney injury (46).  
VIM is a class III intermediate filament of cytoskeleton. VIM is expressed in normal tissues of 
mesenchymal origin and the rapidly proliferating epithelial lining commonly associated with 
cancers and tissue injury. Expression of VIM in proximal tubule cells is allied with pathological 




in vivo was previously found in ischemia-induced injury and nephrotoxic tubular necrosis (47).  
CLU is heterodynamic glycoprotein ubiquitously produced throughout the body (21). 
Up-regulation of CLU in adult tissues has been linked to various disease states but exact biological 
significance of the protein is still unknown (21). CLU was implicated in membrane recycling, 
apoptosis, and even suggested to be a type of stress-induced heat shock protein (21). The body of 
evidence from protein knockout mice (CLU
-/
) suggests that CLU can interact with different 
signaling molecules in affected tissues, promoting or inhibiting cellular death (48). In vivo in the 
proximal tubule epithelial cells, CLU up-regulation has been associated with both ischemia- and 
drug-induced kidney damage (49).  
HO-1 is a microsomal enzyme that catalyzes conversion of heme to biliverdin, producing iron 
and carbon monoxide (22). In injured tissues up-regulation of HO-1 is associated with protective 
response against oxidizing agents (22). In vivo, induction of HO-1 has been previously reported in 
the case of cisplatin, hydrogen peroxide, nitric oxide, endotoxin, cytokines, ultraviolet A irradiation, 
shear stress, hyperoxia, and oxidized low-density lipoproteins (LDL) (22).  
Spp1 is a structural glycoprotein highly preserved among different species. Spp1 is a 
multi-potent agent whose role in kidney damage is two-fold: Spp1 acts as chemoattractant for 
inflammatory cells and may play an anti-apoptotic cellular role. In vivo, Spp1 was found to be 
significantly elevated in nephrotoxic and ischemic forms of AKI and together with CLU and NGAL, 
Spp1 is considered to be a most potent early predictor of kidney tissue injury (23).    
In this study, all gene biomarkers were assessed using qPCR at their corresponding EC50 




organoid cultures. HEK 293 cell line showed no induction of nephrotoxicity-associated genes 
except for VIM in the case of doxorubicin. LLC-PK1 cells had greater but still rather limited 
induction of biomarkers: up-regulated NGAL, VIM, and HO-1 after treatment with PAP; NGAL, VIM, 
Spp1, and HO-1 after exposure to cisplatin; and VIM when exposed to doxorubicin. Unlike 
immortalized cell lines, primary PT cells induced all tested gene biomarkers for all tested drugs. 
Furthermore, except for NGAL, transcriptional stimulation in the 3-D PT cell culture, unlike 
immortalized cell lines, resulted in mostly statistically significant up-regulation, reflecting greater 
reproducibility of mRNA increase in this model vs. traditional 2-D culture. Lack of significant NGAL 
stimulation was most likely due to the fact that NGAL is induced only after significant degree of 
tissue damage (46). Here mRNA was collected after 3 days and might have been extracted from 
cells under recovery. Overall, data closely followed other immortalized cell studies that showed 
inability of such cells to replicate animal data, and in vivo rodent and human studies used to 
elucidate and validate gene biomarkers (50).        
Conclusions 
This study focused on assessing the ability of primary 3-D organoid cell cultures of proximal 
tubules and immortalized kidney cell lines grown using traditional 2-D culture methods to respond 
to nephrotoxic drugs with known in vivo-relevant toxicity biomarkers. Significant differences were 
found between the drug responses of 2-D and 3-D kidney cell culture models. Immortalized cell 
lines responded to nephrotoxic agents with no or limited induction of NAG and 




NGAL, and HO-1 genes , and produced no in vivo-relevant CYP down-regulation. By contrast, 3-D 
hydrogel-based PT tissue culture allowed relatively unhindered drug and media diffusion and 
responded to drugs with biomarkers similar to animal and clinical published data. Furthermore, 
3-D organoid PT model cultures were more sensitive to toxic insult compared to immortalized cell 
lines. Overall, current work indicates that stabilization of cellular differentiation status via 
preservation of in vivo tissue architecture in 3-D culture induces clinically relevant toxicity 
biomarkers. This study provides further validation for the use of semi-synthetic extracellular 
matrices based on HA to evaluate drug toxicity in an in vitro setting that better mimics in vivo 
nephrotoxicity outcomes. 
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Supplemental Figure 5.1. Dose-response curves for doxorubicin (A-C) and cisplatin (D-F) in 




































Supplemental Figure 5.2. TNF-α expression on cultured cell surfaces at drugs’ EC50 values in 
different kidney cell cultures normalized to cell number (LLC-PK1 and HEK293 are 2-D 




































Supplemental Figure 5.3. CYP2B1 intracellular expression at drugs’ EC50 values in different 
kidney cell lines normalized to cell number (LLC-PK1 and HEK293 are 2-D monolayers on plastic; 











































Supplemental Figure 5.4. CYP2E1 intracellular expression at drugs’ EC50 values in different 
kidney cell cultures normalized to cell number (LLC-PK1 and HEK293 are 2-D monolayers on 





SUMMARY AND FUTURE WORK  
Summary 
Kidney toxicity or nephrotoxicity is a pathological condition that commonly occurs as a result 
of drug or environmental exposure (1). Proximal tubule (PT) epithelial cells that line proximal 
tubules (Figure 2.3H) are the most frequently affected part of the kidney, due to the large surface 
area and reabsorption function of these cells (1). Although kidney toxicity is a major medical 
problem, there are no in vitro models that can reproducibly and reliably reflect pathological cellular 
mechanisms of the condition. Current (Chapter 5) and previous literature indicate that current in 
vitro models that primarily rely on immortalized cell lines cultured on two-dimensional plastic 
supports (1), are incapable or highly limited in their ability to reproduce typically measured in vivo 
indicators of nephrotoxicity -- induction of CYP enzymes (CYP2B1 and CYP2E1, Chapter 3,5), 
drug metabolism (Chapter 3), inflammatory mediators (Kim-1, IL-6, TNF, MCP-1, IL-1β, MIP-1α, 
RANTES, Chapter 3) and genes of toxicity up-regulation (CLU, VIM, NGAL, Spp1, HO, Chapter 5) 
(2), and enzyme shedding (γ-glutamyl-transferase brush border and 
N-acetyl-ß-D-glucosaminidase intracellular enzymes, Chapter 5). Furthermore, commonly 
practiced differences in culturing conditions can result in extreme variability within the produced 
data as well as in vivo-irrelevant toxicological data (Chapter 4). Nevertheless, the differences 
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between clinically obtained results and in vitro data most likely reflect limited structural similarities 
between the kidney tissue in vivo and transformed cell lines. Specifically, immortalized kidney cells 
were shown to lack or have minimal expression of drug transporters and cell ligands (3) that are 
involved in drug up-take (4-11), intracellular drug targets (12), drug metabolizing CYP enzymes 
(Chapter 5) and enzymes that may be involved in drug biotransformation (13). Hence, these 
cellular models are intrinsically limited in their ability to facilitate in vivo-like cellular damage 
processes (Chapter 4). This work presents a new model of proximal tubule-centered 
nephrotoxicity that unlike other models published in the literature overcomes the above mentioned 
problems and can respond to environmental assaults with clinically-relevant biomarkers such as 
proteins Kim-1 and TNF-α; N-acetyl-ß-D-glucosaminidase and γ-glutamyl-transferase enzymes 
enzyme shedding; HO, Spp1, CLU, VIM toxicity gene up-regulation; MCP-1, RANTES, MIP-1α, 
IL-1ß, IL-6 cytokine release; cytochrome CYP2E2 and CYP2B1 induction; and metabolite 
production (Chapter 3). The model was created by encapsulating whole fragments of the proximal 
tubules that contain proximal tubule epithelial cells in a hyaluronic acid (HA) gel. The design 
retained cell-cell, cell-matrix, and tissue architecture that were hypothesized to promote cellular 
differentiation and functional stability in vitro. Biomarker production was assessed in response to 
nephrotoxic molecules -- cisplatin, colchicine, PAP, and doxorubicin. The obtained results 
indicated significant similarities in production of toxicity indicators between in vivo and 3-D 
organoid cultures of proximal tubules (Chapter 3), suggesting that preservation of in vitro cellular 
phenotype through recapitulation of the cells’ native microenvironment is critical to making in vitro 
models that can respond to toxicity with clinically-relevant cellular damage. Observations of 3-D 
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cultured PTs established fundamental rules that must be considered when developing in vitro 
models with clinical importance and proving that appropriate in vitro culture systems can respond 
to toxic agents with a wide variety of in vivo biomarkers.  
Future Work 
The results described in the body of this work demonstrated the powerful influence the native 
microenvironment has on primary cell differentiation and functional potential. In vitro preservation 
of cell-cell, cell-native matrix, and 3-D architecture are crucial for retaining in vivo-like cell 
characteristics as well as their ability to function as a tissue unit in response to toxic exposure. 
Using this information as the stepping stone, several avenues for future research can be 
suggested to improve the model’s long-term culturing, physiological relevance, and high 
throughput (HTS) capability. 
Improvements to HTS potential of the model 
The biggest obstacle in using the proposed 3-D organoid PT model is proximal tubule 
isolation. The current isolation method 1) takes over 2 hours to process the PTs from a mouse to 
encapsulation in the 3-D HA culture, 2) is labor intensive, and 3) has a relatively small yield. 
Several alternative methods have been discussed in the literature, including gradient methods 
(Percoll size and density purification) (14), mechanical isolation (iron oxide perfusion, purification 
by sieving, and magnetic removal of glomeruli) (14), surgical microdissection (15), and flow 
cytometric isolation (16). Gradient methods are similar in principle to the method used in this work 
and therefore have similar issues. Use of larger animals, such as rabbits (15), may allow for 
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surgical isolation of proximal tubules; however, the protocols are equally labor intensive, 
expensive, and not applicable to HTS studies. Miller et al. published a method for automated 
isolation of the collective ducts using flow cytometry on kidney digests from transgenic mice 
expressing green fluorescent protein (GFP) in that part of the nephron (16). Unfortunately, the 
protocol involved genetically altered species, had small yield, and required exclusive use of 
non-sterile worm sorters as the regular flow cytometry equipment cannot handle the size of the 
organoid fractions (16). A more HTS applicable model may involve use of thin kidney slices that 
are encapsulated in the gel. There are several advantages to such a model. Automated methods 
for organ slicing that can reduce the thickness of tissue slices as well as minimize human labor 
associated with their preparation have been published (17). Additionally, this method has a much 
greater yield of nephron sections, which would improve the ‘signal’ levels in the collected data. 
Although this isolation and culture method may initially seem superior, it cannot be underestimated 
that minimization of tissue thickness is an important variable in increasing oxygen and nutrient 
diffusion to the cells in a 3-D culture that lacks blood vessels. Nevertheless, introduction of the 
automated method would reduce tissue handling times, improving the reproducibility of the 
procedure and increasing the number of tissue fragments that can be created per kidney and per 
unit of time. All of these improvements would be of significant value to HTS methods. It is 
important to note that the downside of using kidney (or any tissue) slices vs. isolated organoid 
structures is that each slice would contain many different cell types, increasing the ‘noise level’ in 
the acquired data. For example, kidneys contain ~20 different cell types (18) and are likely to 
severely increase the signal-to-noise ratio in measurements. Hence, empirical evaluation would be 
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required to evaluate the value and relevance of the data collected from these models as compared 
to in vivo measurements. 
Improvements to histological/ TEM avaluation of the model 
One of the difficulties with using the 3-D HA model is its incompatibility with common tissue 
techniques such as histology or TEM. Both of these techniques are of significant value to 3-D 
toxicological assessment due to significant knowledge associated with morphological changes 
during nephrotoxicity (19). The gel (1.5% CMHA,7.5% PEGDA) is too soft for easy slicing that is 
done during both procedures. Hence, use of the gel that is easy to degrade, such as HA with 
cleavable bonds might be of significant value. The remaining tissue (PTs or slices) can be 
embedded into materials more suitable for TEM and histological assessment. An example of such 
gel can be CMHA with disulfide-containg crosslinkers, PEG(SS)DA, PEG(SS)2DA, PEG(SS)3DA 
(20). These gels can be broken down using mild reducing and cell-comparible agents such as 
N-acetyl-cysteine or glutathione (20). Furthermore, other techniques, such as RNA isolation for 
RT-PCR and qPCR, might also benefit from using easily degradable HA, because it is almost 
impossible to remove all the gel from RNA preparation using TRIzol® solubilization method.      
Improvements to cell viability 
One of the major downsides of the presented 3-D organoid model was limited cell viability in 
3-D culture. The data indicated that this was most likely due to the inadequate oxygen delivery to 
the deep layers of the gel. Having a profused system instead of the static system would greatly 
improve the oxygenation of the 3-D constructs. This could be achieved by coverting the culture 
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system to either a plate design (Figure 6.1) with an integrated profusion system with or without 
Transwell® inserts (Figure 6.1B) or to a bioreactor.   
Figure 6.1 shows a possible design for the profusion plate that could be used in combination 
with existing Transwell® technology. The design is focused on creation of a novel multitasking 
tissue culture plate that would enable simplified cell surveillance. The primary advantages of the 
design are improvements in 3-D culture profusion as well as the possibility of simultaneous types 
of environmental exposure. The proposed prototype plate is a modification of a 12-well tissue 
culture plate, but the suggested alterations can be applied to any size plate already on the market. 
The primary features of the prototype are small pipes under valve control that can connect wells 
within the tissue culture plate or similarly can be joined with a dynamic profusion system (Fig 6.1A). 
The system of valves within the plate will allow for as many as 12 different parameters to be 
assessed simultaneously, where both the timing and length of the exposure can be modulated by 
the researcher (Fig 6.1C and D). The experimental setup can be further customized by addition of 
a profusion system or a pump to explore conditions of shear stress and flow (Fig 6.1A). All wells 
would be protected by a 0.22µm filter inserted at the joint with the pipe to prevent 
cross-contamination and sterility of the plate. The design can be applied to 12-well plates with 
inserts (as shown in Figure 6.1) or to 96-well plates. Table 6.1 summarizes advantages of the 
profused plate design over the traditional static Transwell® system. 
Use of bioreactor with a profusion system is another option. Many different prototypes can be 
found in the literature or purchased from commercial vendors. 3D Bioteck™ bioreactor is a good 




Figure 6.1. Possible profusion plate layout. A) Transwell® prototype-plate layout, B) Corning 
transwell, C) Transwell® prototype-section that shows the placement of gate micro valves, D) 















 Table 6.1 Comparison of profused plate to the Transwell® 12-well Corning® plate 





Each well has an insert with 
a filter that can support cell 
growth. Different cells are 
cultured on the tissue culture 
polystyrene (bottom) and 
polycarbonate or polyester 
membrane of the insert (top) 
Cells are expanded on the tissue 
culture polystyrene at the bottom 
of the wells. Different cells can 
be plated in different wells and 
communication can be 
established my opening a valve 
in the connecting pipe 
 
 
Effect on culture O2 supply 
Cells grown on the filter and 
the bottom of the well will 
see different  O2 





Flow and shear stress 
studies 
No Yes 
Requires different models 















the 3-D organoid or 3-D tissue slice design. Alternatively, the 3D Profusion Bioreactor® (3D 
Bioteck™, USA) is small enough to fit into a cell culture incubator and can hold up to 120 
constructs at the same time. The entire unit, with the exception of the pump, can be pressure and 
steam sterilized and can be used with a wide size range of 3-D scaffolds. 
Future data analysis 
The most exciting finding of the 3D organoid model was discovery that for the first time a wide 
range of in vivo-relevant biomarkers can be assessed from an in vitro culture system. This allows 
the direct comparisons between animal and in vitro cultures using libraries of drugs with known 
nephrotoxic properties (e.g., cisplatin,  nomifensine, methoxyflurane, PAP, colchicine, doxorubicin, 
ifosfomide, geftinib, cyclophosphamide, mithramycin, azacitidine, methotrexate, imatinib, 
pentostatin, bisphosphonates(19))  and established biomarkers (e.g., cytokines -- Kim-1, NGAL, 
MCP-1, TNFα, RANTES, MIP-1α, IL-1ß, IL-6, IL-18, enzyemes -- N-acetyl-ß-D-glucosaminidase 
and γ-glutamyl-transferase, cytochromes -- CYP2E2 and CYP2B1, and genes of toxicity -- HO, 
Spp1, Kim-1, NGAL, CLU, VIM, RBP, AA819244 EST, IGF-BP3, Sgp2, β-alanine-pyruvate amino 
transferase, vitamin D binding protein, class I beta-tubulin, UDPGT, EGF, nerve growth factor, 
P4502D18, AA957270 EST, sytaptonygrin 2, BHMT, AA925142 EST (20)). Although there is no 
expectation that 3-D cultures would be able to respond with every biomarker to every drug, the 
direct comparison of several molecules would allow the establishement of a rubric outlining the 
impact of individual ‘positive’ biomarker assays as well as the statistically relevant change in 
biomarker levels required for the overall determination of predictive in vitro toxicity (Chapter 1).  
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Although no in vitro culture system will ever perfectly mimic the exact sensitivity or tisse response 
of an in vivo system, empirical evaluation of the most dependable, sensitive, and reproducible 
assays are needed for in vitro-in vivo comparisons. The 3-D organoid culture model described 
herein presents a significant step toward this lofty goal.    
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Protocol:  PT media     
Date Originated: 12/2/11 
Revision Date  Reviser Name: 
Original Author:  Astashkina A   
Reference(s):  Terryn et.al.“A primary culture of mouse proximal tubular cells, established on 
collagen-coated membranes” Am J Physiol Renal Physiol 293: F476–F485, 2007;   
 
 
Required Equipment: BSL 2 hood, 50 sterile ml t.t.  
 
Materials Needed: 
• FCS  
• Anti-anti  
• Sodium pyruvate 
• Insulin/transferrin/selenium 
• DMEM:F12 (no phenol red) 




Estimated Time: 10 min  
Before you Begin: FCS and anti-anti is -20º fridge across my bench in the cell-media 
components shelf.  Hydrocortisone is stored at -20º in the corner fridge by -80º freezer in my box . 








Sodium pyruvate -275 µL 
Non-essential am.ac.-500 µL 
Insulin/transferrin/selenium- 500 µL 
Hydrocortisone - 18 µL 
Anti-anti-500 µL 
DMEM:F12 (no phenol red)-47.707mL 
 
Store in 50ml sterile t.t at -20ºC fridge. 
 











Protocol:  PT isolation and making of 3D constructs    
Date Originated: 12/2/11 
Revision Date  Reviser Name: 
Original Author:  Astashkina A   
Reference(s):  Terryn et.al.“A primary culture of mouse proximal tubular cells, established on 
collagen-coated membranes” Am J Physiol Renal Physiol 293: F476–F485, 2007;   
 
 
Required Equipment: BSL 2 hood, 50 mL and 1.5 mL sterile t.t, sterile surgical tools, and 
autoclaved 250µm sieve, sterile 70 µm filters, UVed razor blade, non-tissue culture treated sterile 
large plates (bacterial).  
 
Materials Needed: 
• Ice-cold KREBS 
• Warm PT media 
• Resuspended HA and PEGDA 
• Sterile enzyme solution 
 
 
Estimated Time: 2-5 hours  
 
Before you Begin  
Before starting PT isolation, you need to have sterile KREBS, enzyme digestion solution, 
polymers, sterile surgical tools, and sterile large 250µm filter ready. Enzyme solutions and 
polymers are made right before each experiment. You need to plan starting making your enzyme 
and polymer solutions about 2 hours before the start of the experiment, because HA takes almost 
1 hour to resuspend. I do not autoclave razor blades (for mechanical kidney disruption) because 
they get dull. Spray razor blade with 70% ethanol and UV it in the hood for 20 min before staring 
PT isolation. 
 
Before getting mice, your hood should have the following items: sterile tools, UVed razor blade, 
sterile enzyme solution, sterile non-tissue culture round plates, cold KREBS, and 70% ethanol-
spayed paper towel (for animal surgery).  
 
 
Solutions and chemicals: 
 
1. KREBS: 145 mM NaCl, 10mM HEPES, 5 mM KCl, 1mM NaH2PO4, 2.5 mM CaCl2, 
1.8 mM MgSO4, 5 mM glucose, pH 7.3) 
 
To make 1L of KREBS: 
NaCl-        8.48g 
HEPES-    2.38g 
KCl-          0.373g 
NaH2PO4- 0.12 g 
CaCl2-       0.277g 
MgSO4-     0.217g 
D-glucose- 0.9g 
 
Resuspend all chemicals in 1L of dH2O, pH to 7.3 with KOH, sterile filter using 0.22µm 






2. Enzyme solution: 10ml KREBS+2mg/ml hyaluronidase +3mg/ml collagenase IV + 
0.1mg/ml DNase I  
 
You need to make 5mL of it for each mouse. For 5mL enzyme solution: 
Collagenase IV (Worthington, cat# LS004188) - 15mg  
DNase I (Sigma, cat #DN25-100mg) - a tiny speckle 
Hyaluronidase (Worthington, cat# LS002592) - 10mg 
 
Combine all chemicals in 50 mL t.t., sterile filter into another 50 ml t.t. using 0.22 µm filter 
in the hood. Store in 4º fridge before experiment. 
 
 
3. Polymers:  Take out (from -80º freezer) and defrost HA for 30 min before weighing 
(because it is so hygroscopic). I use 1.5% HA (15mg/1000mL) and 7.5% PEGDA 
(75mg/1000mL) to make my gels. I resuspend dry chemicals in sterile (cell culture 
grade) PBS
++ 
 in the hood, but PBS
- - 
or full media should also be fine (just stay 
consistent). It takes almost 1 hour at RT on the shaker for HA to go into solution. 
Once PEGDA and HA are resuspended, sterile filter them with 0.22 µm filter in the 
hood. Store at RT before the experiment. Do not freeze, UV, or reuse unused 
HA/PEG.  I make about 1.3mL of HA and 500µL per mouse. 
 
For each well you will use 40 µL of HA and 10 µL of PEG (4:1 HA:PEG). When PEG and 
HA are mixed with cells, each well in a 96 well plate should get about 52 µL (to account 







1. Black C57 mice should be killed in the animal facility using CO2 and brought back to the 
lab as soon as possible. 
2. Spray all mice with 70% ethanol prior to bringing them in the hood. 
3. Open mouse abdomen and remove kidneys (they are large, bean shaped organs on the 
posterior side) and place them in ICE COLD KREBS in a non-tissue culture plate. 
4. Remove blood vessels, ureter, and thin film that surrounds the organ. Place cleaned 
kidneys in ICE COLD KREBS for storage (if you are doing more than 1 mouse).  
5. Take out kidneys from KREBS and finely mince them using sterile razor blade. 
6. Put minced kidney into enzyme solution and digest for 30 min SHAKING at 37ºC (in the 
water bath). 
7. Add 10-15 ml of cold KREBS to the digested kidney, pipet up and down, filter through 70 
µm filter (sterile small filters). DISCARD the flow through.   
8. Kidney pieces that were greater than 70 µm (what was left in the filter) should be filtered 
again through 250 µm filter (large metal filter) using 20mL of KREBS. KEEP the flow 
through (20mL total volume). 
9. Take out 300 µL of the PT suspension from step 8 and put it into 1.5mL t.t. (for counting). 
10. Spin 20mL of PTs in KREBS (from step 8) in the large centrifuge at 12,000 rpm for 12 
min. Simultaneously spin 300 µL in the smaller centrifuge for 5 min at max speed. 
11. When 300 µL(for counting) t.t. is done spinning, remove all solution and resuspend PTs 
in 30 µL (concentrating sample 10 times). Count PTs using hemocytometer, calculate 
concentration (remember to multiply by 0.1 dilution factor). Calculate how much PEG and 
HA needs to be added to get 5000 PTs/well 
12. When 20mL t.t. is done, remove all solution and add calculated amount of PEGDA and 




13. Put 52uL of step 12 mixture into Teflon-coated 96 well plates. You will have to use you tip 
to spread the drop in the well. 
14. Let the gel crosslink for 30 min in the incubator. After 30 min the gel should be almost set 
(you can tilt the wells to see if the gel is running). Add 100-150 µL of warm PT media to 
each well. Do not directly pipette on the top of the gel because it is usually too soft and 
may change shape. I add media to the wall of the well, and let the drop slide onto the gel. 




Notes: I buy all enzymes from Worthington. The company has a layaway program where 
they store 3g of each enzyme lot for future purchase. Since each lot varies in activity, use 
of the same lot is highly suggested.  If you enzyme strength changes, you will most likely 
have to adjust the incubation time with the enzyme or the concentrations of enzymes in 











Protocol:  making TeflonAF® plates     
Date Originated: 12/2/11 
Revision Date  Reviser Name: 
Original Author:  Astashkina A   
Reference(s):     
 
 
Required Equipment:  Hood with UV lamp 
 
Materials Needed: 
• Resuspended TeflonAF 




Estimated Time: 3-4 hours  






1. Make sure you use NON tissue culture 96 well plates 
2. Only coat 2-3 rows/plate because Teflon is very expensive and you will not be using 
more than 3 rows for any experiments 
3. Add 150uL of Teflon AF to each well  
4. Put for 2 h in the dry oven at 57C (mark #3) to evaporate organic solvent  
5. UV is the hood for 20-30 min 
6. Parafilm and store at RT 
 











Protocol:  Immunohistochemistry for 3D PT constructs    
Date Originated: 12/2/11 
Revision Date  Reviser Name: 
Original Author:  Astashkina A   
Reference(s):     
 
 




• PBS with NaAzide (1% or 0.08%) 
• 4% paraformaldehyde 
• Triton X 
• iT signal enhancer 
 
 
Estimated Time: 1-7 day procedure  





1. Remove all the media and add 4% paraformaldehyde. Incubate overnight in a 4ºC fridge 
2. Wash with PBS (with NaAzide) 2X times   
3. If you are staining for markers on the cell surface, skip to item #4. If staining for intracellular 
markers, then add 0.1% Triton X (in PBS with NaAzide) for 20 min. Wash 2X times 
4. Add iT signal enhancer (Invitrogen)- about 1-2 drops per culture-for 30min. Incubate at room 
temperature (RT) 
5. Wash with PBS (with NaAzide) 2X times   
6. Add primary antibody. The final concentration and time of incubation might have to be 
optimized for each antibody. I used anywhere from 1:500 (for Kim-1) to 1:2000 (for OAT-1). 
Most primary antibodies worked well at 1:1000. Usually 100uL/well of final concentration is 
enough. Majority of antibodies stained well after 3 days in a 4ºC fridge (but I also had to 
reduce time to 2h at RT for  OAT-1 and increase to 7 days for AQP-1) 
7. Wash with PBS (with NaAzide) 2X times   
8. Add secondary antibody for 1.5-2h at RT (cover with foil during incubation). If you need to do 
nuclear stain, use PI (I tried many other stains, and they do not look good, or look diffused on 
confocal image). PI needs 10-20 min to stain the 3-D culture (long incubation can result in the 
entire PTs turning red). 2uL/well tends to be enough.  
 






Protocol:  RNA extraction using TRIzol Reagent for 3D PT constructs    
Date Originated: 12/2/11 
Revision Date  Reviser Name: 
Original Author:  Astashkina A   
Reference(s):     
 
Required Equipment: RNAse-free tips and 1.5 mL t.t., working area cleaned with RNAse spray, 
hand-held tissue terror wiped with RNAse-free wipe 
 
Materials Needed: 
• 75% ethanol 
• Trizol 




Estimated Time: 2 day procedure  
Before you Begin: Mix 75% ethanol: 7.5 ml 200proof ethanol + 2.5 ml DEPC treated water 
Turn on dry bath to 56°C. 
Clean a crucible with pestle with RNAse away. Cool to -80°C if you will be using it in step 2. 







1. Take off media. Add Trizol 200uL directly to constructs. Pipette up and down to dissolve 
as much as possible. Transfer to the crucible. 
2. Add 590 ul of Trizol+10uLof glycogen to crucible. Mechanically break down undissolved 
chunks with pestle. NOTE: you do not need to mechanically break constructs when you 
think you will get plenty of RNA. You can just add 590 ul of Trizol+10uLof glycogen to 
1.5mL RNase-free t.t.  
3. Move 800uL of dissolved 3D constructs in TRIzol/glycogen from crucible into one 1.5 ml 
microcentrifuge tubes (RNAse-free). If you did not mechanically break down 3D 
constructs, move 200uL of supernatant with dissolved 3D construct to 1.5 ml 
microcentrifuge tube that already had 590 ul of Trizol+10uLof glycogen to crucible 
(making total volume 800uL). Use hand-held tissue terror to further mince tissues. 
4. Centrifuge at 12,000 g for 15 min at 4C 
5. Collect the supernatant (RNA will be in supernatant) and transfer it into a new RNAse-
free tubes. Discard the pellet that has gel and cell membranes. 
6. Add 160ul of chloroform to eppendorf ( 0.2 ml chloroform per 1ml TRIzol® 
7. Shake tube vigorously by hand for 15 seconds. 
8. Centrifuge the samples at 12,000 g for 20 minutes at 4ºC.  
9. Following centrifugation, the mixture separates into a lower red, phenol-chloroform 
phase, an interphase, and a colorless upper aqueous phase (see pictures). RNA remains 
exclusively in the aqueous phase. The volume of the aqueous phase is about 60% of the 
volume of TRIzol® Reagent used for homogenization. 
10. Transfer the aqueous phase to one RNAse-free 1.5ml fresh tube. Precipitate the RNA 
from the aqueous phase by mixing with isopropyl alcohol. Use 400 ul of ice-cold isopropyl 




11. Centrifuge at 20,000 g for 15 minutes at RT. The RNA precipitate, often invisible before 
centrifugation, forms a gel-like pellet on the side and bottom of the tube.  
12. Discard the supernatant. Wash the RNA pellet once with 75% ethanol, adding 200ul to 
eppendorf. 
13. Mix the sample by vortexing and centrifuge at 20,000 g for 10 minutes at 4C. 
14. Discard the wash and air- dry the RNA pellet for 5-10 minutes. It is important not to let 
the RNA pellet dry completely as this will greatly decrease its solubility.  Dissolve 
RNA in 30uL RNase-free water and incubate for 10 minutes at 55 to 60°C in the drybath.  
15. Add 1uL of DNAse I and incubate for 30 min at 37°C. 
 
 












Protocol:  CyQuant NF for 3D PT constructs     
Date Originated: 12/2/11 
Revision Date  Reviser Name: 
Original Author:  Astashkina A   
Reference(s):    see Invitrogen manual for CyQuantNF 
 
 
Required Equipment: spectrophotometer 
Materials Needed: 







Estimated Time: 1.5-3.5 h procedure  






1. Take off media. Wash 1X with sterile PBS. Wash more if you were using phenol-
containing media 
2. If you are comparing to gel with no cells, you need to incubate all constructs for 1 hour 
0.01mM H2O2. Wash 1X again. If you are comparing to gel with cells (no treatment 
control), you can skip step#2 
3. Add 100uL of CQ solution, incubate for 1h in the incubator 
4. Remove CQ solution (pipette up and down, try to not get bubbles) and plate it in a new 
96 well plate. Read fluorescence at 485 nm excitation and 530 nm emission 
 











Protocol:  qPCR for 3D PT constructs     
Date Originated: 12/2/11 
Revision Date  Reviser Name: 
Original Author:  Astashkina A   
Reference(s):    Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-
time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001 Dec;25(4):402-8. 
 
 
Required Equipment: RNAse-free tips and 1.5 mL t.t., working area cleaned with RNAse spra, 
Step One Plus qPCR cycler (Kim’s lab) 
 
Materials Needed: 




Estimated Time: 2-3 hours  





1. Measure RNA concentration using Nanodrop (In Lim’s or Kim’s Lab). Dilute your samples 
to 100 ng/µL (good RNA quality) or 300ng/µL (poor RNA quality). I used 300ng/µL 
2. Use RNA-CT Taqman Kit (Applied Biosystems, USA) because it is more sensitive to poor 
RNA quality material 
3. Follow manufactures instructions for kit dilution 
4. Run 2-3 technical replicas per sample 
5. Use GAPDH as internal control. Always run GAPDH on the same plate as samples and 
for every condition  
6. I analyzed QPCR data using the 2
-ΔΔC
T method. It measures only by how much gene 
expression increased or decreased, not the actual number of RNA copies in the cell. 
Samples that did not express genes after 40 cycles were assigned 41-cycle expression 
for calculations  
 
 
qPCR I performed used commercial TaqMan® Gene expression Assays (Applied Biosystems, 
USA): Mm9999915_g1 for GAPDH, Mm01324470_m1 for Lcn2 (NGAL), Mm004427773_m1 for 
CLU, Mm00516005_m1 for HO, Mm01333430_m1 for VIM, Mm00436767_m1 for Spp1 
 
Notes: RNA-CT Taqman Kit is usually located in the door of the 4ºC media fridge. TaqMan® 
Gene expression Assays are in the door of the -20ºC fridge. If you are using Kim’s lab machine, 







Protocol:  NAG measurement     
Date Originated: 12/2/11 
Revision Date  Reviser Name: 
Original Author:  Astashkina A   
Reference(s):   Barcelos LS, Talvani A, Teixeira AS, Vieira LQ, Cassali GD, Andrade SP, et al. 
Impaired inflammatory angiogenesis, but not leukocyte influx, in mice lacking TNFR1. Journal of 
leukocyte biology. 2005 Aug;78(2):352-8. 
 
 
Required Equipment:  
Materials Needed: 
• p-nitrophenyl-N-acetyl-β-D-glucosaminide (Sigma Aldrich, USA) solution 
• 1 mM 4-nitrophenol standard 
  
 
Citrate/phosphate buffer: 0.1 M citric acid, 0.1 M Na2HPO4, pH 4.5 
p-nitrophenyl-N-acetyl-β-D-glucosaminide solution: 2.24mM in citrate/phosphate buffer 
 
Estimated Time: 20 min 





1. Collect the media (no phenol red) with NAG 
2. Incubate 100 µL of media for 10 min at room temperature with 100 µL of 2.24mM p-
nitrophenyl-N-acetyl-β-D-glucosaminide solution. 
3. Read absorbance at 405 nm on the microplate reader and referenced against a 1 mM 4-




Notes: NAG can be measured only in solution, inside cells there is too much interference with 
intrinsic cellular absorbance. It is strongly suggested for you to keep your media+ drug and 
measure its absorbance at 405 nm. You can subtract the dug+media background from your 
samples.   
 
 
 
